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1. Zusammenfassung 
Parasitische Würmer wie Filarien können das Immunsystem ihres Wirtes effektiv modulieren 
und so über viele Jahre im Wirt persistieren. Diese Immunmodulation schützt nicht nur den 
Parasiten, sondern kann auch einen Schutz des Wirtes vor allergischen Reaktionen vermitteln. 
Es scheint, dass Wurminfizierte weniger Allergien bekommen. Parasiten sezernieren 
immunmodulatorische Moleküle die in engem Zusammenhang mit Immunevasion stehen und 
starke anti-allergische und anti-inflammatorische Eigenschaften haben könnten. In der 
vorliegenden Arbeit wurde Filariencystatin, ein sezernierter Proteinaseinhibitor des 
Fadenwurms Acanthocheilonema viteae in Allergiemodellen eingesetzt.  
Filariencystatin supprimierte Th2-assoziierte Entzündungen und die daraus resultierende 
Atemwegserkrankung in einem murinen Ovalbumin-induzierten Asthmamodell. Die 
Behandlung der Tiere mit Cystatin während und ebenso nach Abschluss der 
Sensibilisierungsphase und vor der Atemwegsprovokation mit Allergen, verhinderte die 
Atemwegsentzündung und –hyperreaktivität, reduzierte allergen-spezifisches IgE und regelte 
die IL-4 Produktion herab. Diese Effekte von Cystatin beruhen wahrscheinlich auf der 
Induktion von IL-10 sezernierenden Makrophagen. Dafür spricht, dass sowohl die Depletion 
von Makrophagen durch Clodronat gefüllte Liposomen, als auch die Blockierung von IL-10 
durch anti-IL-10-Rezeptor Antikörper den schützenden Effekt von Cystatin aufhoben und die 
allergische Entzündung wiederherstellten. Im Gegensatz dazu hatte die Entfernung von 
regulatorischen T-Zellen durch anti-CD25 Antikörper nur sehr begrenzte Effekte auf die 
Cystatinwirkung. 
In einem murinen Allergiemodell der Haut (Ovalbumin-induzierte atopische Dermatitis) 
konnte durch Cystatinapplikation die Entzündung der Haut und die allergische Erkrankung 
ebenfalls supprimiert werden. Die Ekzembildung und das Einwandern von inflammatorischen 
Zellen in die Hautläsionen war ebenso behindert, wie die Bildung von allergenspezifischem 
IgE. Die Verbesserung der atopischen Dermatitis führte zu einem dramatischen Anstieg von 
TGF-ß in den Ekzemregionen.  
Zusammenfassend belegen die vorliegenden Daten, dass ein einzelnes rekombinantes 
Helminthenprotein den anti-allergischen Effekt einer Gesamtwurminfektion nachahmen kann. 
Ein weiterer Aspekt dieser Arbeit war herauszufinden, ob die Immunmodulation von 
Helminthen an die Biologie bzw. die Lokalisation des Wurmes gebunden ist. In zwei 
verschiedenen Allergiemodellen, der mucosa-assoziierten allergischen Atemwegsentzündung 
und der nicht-mukosa-assoziierten, kutanen atopischen Dermatitis wurde der Einfluss einer 
gastrointestinalen Wurminfektion mit Heligmosomoides polygyrus untersucht. Im 
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Asthmamodell konnte eine deutliche Reduzierung der Inflammation in wurminfizierten 
Mäusen beobachtet werden. Im Gegensatz dazu zeigten wurminfizierte Mäuse im Dermatitis 
Modell keinerlei Verbesserung des klinischen Bildes. Im Asthmamodell führte die 
Wurminfektion zu signifikant erhöhten Werten von Foxp3+ regulatorischen T-Zellen (Treg) in 
peribronchialen Lymphknoten. Im Dermatitismodell hingegen konnten keine Treg Zellen in 
ekzematöser Haut nachgewiesen werden und auch in den drainierenden inguinalen 
Lymphknoten war kein Anstieg der regulatorischen Zellen zu beobachten. Das deutet 
daraufhin, dass durch eine gastrointestinale Nematodeninfektion induzierte Treg Zellen zwar 
in andere mukosale Gewebe wie die Lunge migrieren können, jedoch nicht in der Lage sind in 
nicht-mukosale, kutane Gewebe zu wandern. Diese Ergebnisse sind ein wichtiger Aspekt 
beim Einsatz von Helminthen zur Behandlung allergischer Erkrankungen, da die Lokalisation 
des Wurmes ein entscheidender Faktor in Richtung Verbesserung oder Verschlimmerung 
allergischer Erkrankungen zu sein scheint. 
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Summary 
Influence of a nematode immunomodulator and a nematode infection 
on two models of allergic disease 
Parasitic worms, like filariae, have the intriguing capacity to modulate immune responses 
directed against them, and therefore can persist up to years in a host. This immunomodulation 
does not only protect the parasite but was found to mediate a negative correlation between 
infections with parasitic worms and the prevalence of allergic disease. Secreted molecules of 
the parasites were found to be strongly involved in immune deviation and might bear 
themselves strong anti-allergic and anti-inflammatory potential. In the present study filarial 
cystatin, a secreted protease inhibitor of the filarial nematode Acanthocheilonema viteae, was 
found to suppress Th2-related inflammation and the ensuing asthmatic disease in a murine 
model of ovalbumin-induced allergic airway responsiveness. Treatment with recombinant 
filarial cystatin during or after sensitization and before challenging mice with the allergen, 
inhibited airway inflammation and airway hyperreactivity, reduced levels of allergen-specific 
IgE and down-regulated IL-4 production. These effects of Av17 on allergic airway 
inflammation were probably due to induction of IL-10 secreting macrophages. Depletion of 
macrophages by liposomes containing clodronate as well as blocking of IL-10 by application 
of anti-IL-10 receptor antibodies, prevented the curative effects and restored allergic airway 
inflammation. In contrast, depletion of regulatory T cells by anti-CD25 antibodies had only 
limited effects.  
Treatment with cystatin in a model of allergic skin disease, namely ovalbumin-induced 
dermatitis, was determined to have suppressive activity on inflammation and the ensuing 
allergic disease, too. Eczema formation and recruitment of inflammatory cells to lesions was 
clearly impaired and also allergen-specific IgE production substantially reduced. The 
protective effect on atopic dermatitis was accompanied by a dramatic increase of TGF- in 
the eczema region. Hence, the data demonstrate that treatment with a single recombinant 
helminth protein can exert the anti-allergic effects of helminth infections. 
Another part of this study was to investigate if immunomodulation by helminths is dependent 
on the biology (localisation) of the worm. The influence of a gastrointestinal nematode 
infection with Heligmosomoides polygyrus, was analyzed in two distinct murine models of 
allergy: mucosa-associated airway disease and non-mucosal, cutaneous atopic dermatitis. 
Mice concomitantly infected with H. polygyrus clearly showed reduced signs of allergic 
airway inflammation. In contrast, no significant differences in phenotypical signs of 
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dermatitis, such as severity of eczematous skin lesions, were observed between infected and 
control animals in the atopic dermatitis model. Worm infection was associated with 
significantly elevated numbers of Foxp3+ regulatory T cells (Treg) in peribronchial lymph 
node cells in H. polygyrus-infected sensitized and airway challenged mice, whereas Treg cells 
were basically absent in eczematous skin of mice with experimental dermatitis and not up-
regulated in their skin-draining lymph node cells. Therefore, it seems that Treg cells induced 
by a gastrointestinal nematode infection can migrate to mucosa associated lung lymph nodes, 
but are not able to migrate into cutaneous tissue. These findings might be an important aspect 
for future considerations of helminths for treatment of allergic diseases, as localisation of the 
parasites might be a crucial factor leading to amelioration or aggravation of allergic disease. 
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2. Introduction 
2.1. Immune regulation by parasites 
2.1.1. Immune reaction to and immune evasion by parasites 
Parasites are defined as organisms that live in or on and obtain nourishment from another 
organism of a different species (Lucius 2008). Among multicellular parasites the parasitic 
nematodes have a well-balanced host-parasite-equilibrium and thereby display long 
persistence without gravely damaging their host. This equilibrium is partly due to the fact that 
helminths do not replicate in their hosts and high parasite loads can only be accounted for by 
continuous exposure and infection.  
Hosts have a wide variety of mechanisms to fight parasites. As far as helminths are 
concerned, immune reactions comprise the whole repertoire of immune cells. A scenario 
might begin with antigen-presenting cells (macrophages, dendritic cells or B cells) that 
process the foreign worm antigens and display them to T-helper cells in a MHC class II- 
context. T-helper cells start to produce cytokines that activate and attract macrophages and 
other innate immune cells (eosinophils, neutrophils, basophils) as well as B cells and more T 
helper cells. Antigen-specific B cells differentiate to plasma cells and produce large amounts 
of antibodies. Antibodies can opsonise the pathogen to direct eosinophils or neutrophils, as 
well as macrophages, to their target (antibody-dependent cellular toxicity, ADCC). Also, 
antibodies bind to Fc-receptors displayed by mast cells. This sensitizes mast cells, which 
then secrete large amounts of histamine and other mediators once antigen contact ensues, 
facilitating the attraction and accumulation of further immune cells. Furthermore, special 
populations of macrophages (alternatively activated macrophages generated in the presence of 
helminths) were shown to be involved in the termination of secondary infections (Anthony 
2006). 
Intriguingly, some parasitic filariae (Onchocerca volvolus) can persist in their hosts for up to 
15 years (Plaisier 1991). This means that these creatures must have developed strategies to 
escape the host’s immune response in order to survive in the long run. These so-called 
immune evasion mechanisms comprise a large repertoire and lead to avoidance of nearly any 
immune response set up by the host. 
Helminths protect themselves with manifold strategies: their surface, the multilayer cuticula, 
prevents quite a lot of immune reactions, therefore reacting as a biological armour. 
Furthermore, helminths migrate in their hosts and can evade pathology by moving away from 
inflammation. Another evasion mechanism exploited, for example by filariae, is their location 
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in immunological privileged tissue, such as nodules. Additionally, some parasites secrete 
proteases to prevent antibody opsonization and they are able to produce anti-oxidative 
enzymes. Helminths can induce and suppress immune reactions to aid their survival, partly 
systemically and partly locally in direct interaction with immune cells (Maizels 2004). 
Millions of people world-wide are infected with helminths. Generally, only a small percent of 
infected individuals suffer from severe symptoms, but most remain asymptomatic (van Riet 
2007). Helminths are known to skew the immune response towards Th2, characterized by Th2 
related cytokines IL-4, IL-5 and IL-13 that induce B lymphocytes to switch to IgE antibody 
production. However the role of Th2 has been described to be that of eradicating helminth 
infections (Finkelman 2004). 
The question, therefore, is why helminths carry Th2 inducing molecules? Presumably these 
molecules are essential for parasite biology, as could be demonstrated for the filarial protein 
tropomyosin (Sereda 2008). 
As mentioned before, helminths have developed different strategies for survival in their host. 
Schistosomes, for example, can compromise complement function (Ouaissi 1981), may 
degrade host immunoglobulins (Auriault 1981), can acquire surface molecules from their host 
to perform molecular mimicry and may produce cytokine mimics (Maizels 1993). 
Furthermore they can down-regulate B and T cell responses via induction of Tregs, anti-
inflammatory cytokines or AAM (Maizels 2003).  
Longevity of filariae (Subramanian 2004) reflects suppression or modulation of the host´s 
immune system (King 2001, Brattig 2004) such that there is an impairment of lymphocyte 
proliferation and bias in the production of cytokines and antibodies. Generally Th2 –
associated IL-4 and anti-inflammatory IL-10 are increased and associated with elevated levels 
of IgG4 (mouse IgG1), an antibody subclass that is unable to activate complement or bind 
with high affinity to phagocytic cells, thereby having little value in the elimination of 
pathogens. Overall, filarial nematodes lead to a suppressed (impaired lymphocyte 
proliferation), anti-inflammatory (increased IL-10 and IgG4) and Th2-like (IL-4) immune 
response.  
It is thought that such modulation does not only lead to parasite survival, but is conducive to 
host-health by limiting pathology resulting from aggressive immune responses 
(immunopathology) (Harnett 2006). 
Immunomodulation is believed to be beneficial to both host and parasite, as it protects 
helminths from being eradicated, but at the same time safeguards the host from excessive 
immune responses that might lead to pathology. However, it does usually only occur in 
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chronic or high level infections. Interestingly, modulation of immune response seems not only 
to be directed against the worms but also to non-related bystander antigens (van Riet 2007). 
2.1.2. Influence of parasites on systemic immune responses (spillover mechanisms) 
On the one hand, helminth modulation, as in infection with Heligmosomoides polygyrus, can 
impair host resistance to other pathogens like Citrobacter redentium and enhance Citrobacter-
induced colitis (Chen 2005). On the other hand, worm infections (Ascaris lumbricoides) 
protect hosts from the negative effects of Plasmodium falciparum (cerebral malaria and acute 
renal failure) (Nacher 2000, 2001) and H. polygyrus protects from intestinal pathologies, e.g. 
of Helicobacter pylori (Fox 2000, Elliott 2004). 
The immune modulation by helminths has been explained by induction of Treg cells, which 
inhibit the recruitment and the activation of effector cells (Wilson 2005, Baumgart 2006, 
Metwali 2006), by driving the balance between different antibody isotypes (Mutapi 2005) 
and/or T-cell populations (McKee 2004, Gillian 2005). Among the potential mechanisms of 
helminth immunomodulation is also the concept of secreted/released immunomodulators. Up 
to now, cytokine homologs, protease inhibitors, lectins and glycans that may misdirect or 
interrupt host immune response were described. 
Homologs of mammalian cytokines were found in Brugia malayi and pahangi (Gomez-
Escobar 1998) and in Schistosoma japonicum (Hirata 2005) and described to be parasite-
encoded TGF-ß homologs. Protease inhibitors were described as molecules that interfere with 
antigen-processing and presentation of antigen. One of the most important types are cystatins 
(Hartmann 2003; see section 2.1.3.).  
Several glycans derived from Schistosoma eggs were found to expand a Gr1+ suppressor 
macrophage population in the mouse peritoneal cavity that produces high levels of TGF-ß and 
IL-10, thereby suppressing proliferation of naïve T cells ex vivo (Terrazas 2001).  
In addition N. brasiliensis has been described to release a component with acetylhydrolase 
activity that leads to cleavage of platelet-activating factor (PAF). PAF has been shown to 
promote bronchoconstriction, increase vascular permeability and activate inflammatory 
leukocytes (Blackburn 1992). Excretory/secretory (E/S) products of the hookworm Necator 
americanus are able to cleave eotaxin, thereby inhibiting the recruitment and activation of 
eosinophils (Culley 2000). 
Interestingly helminths can, but usually don´t induce strong allergic responses in humans 
(Cooper 2002). There are close similarities between allergic inflammation to environmental 
allergens and to parasite antigens. Both are associated with high levels of IgE, tissue 
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eosinophilia and mastocytosis, mucus hypersecretion and T cells preferentially secreting type 
2 cytokines as IL-4, IL-5 and IL-13 (Yazdanbakhsh 2002, Cooper 2004). In human studies it 
turned out that acute infections may lead to allergic syndromes as Loeffler´s syndrome, which 
occurs when A. lumbricoides larvae migrate through the lungs for the first time (Cooper 
2002). However, in individuals with chronic infections clinical allergic reactions appear to be 
rare. Most intriguingly, Schistosomiasis may decrease immune response to allergens and 
clinical manifestation of asthma (Araujo 2006).  
Thus, helminth infections – although responsible for an overall negative impact on the host‘s 
health – bear the intriguing potential to positively modulate pathological inflammatory 
responses. Evidence for this hypothesis was provided by clinical trials in patients with 
inflammatory bowel disease, in which the eggs of intestinal worms reduced symptom severity 
(Summers 2005 a, b). 
2.2. Hygiene hypothesis 
ISAAC (International study of asthma and allergies in childhood) and ECRHS (European 
community respiratory health survey) studies show that asthma prevalence has increased 
steadily over the last decades (Pearce 2000). 
In 1989 Strachan formulated the hygiene hypothesis in which he suggested that the increasing 
incidence of asthma and allergies could be attributed to reduced exposure to childhood Th1 
polarising infections, because of an increase in vaccination and improvements in sanitation. 
Lacking an imprint of Th1-biased memory cells, the inherent Th2 bias of immune 
responsiveness at mucosal surfaces would proceed unchecked and lead to allergies in 
genetically predisposed individuals. Today, the hypothesis has been modified mainly 
concentrating on exposure to endotoxin in childhood, thereby leading to a Th1 bias (Braun-
Fahrlander 2002). However, an underlying universal immunological mechanism has still not 
been determined (Vercelli 2006).  
Furthermore, there are several arguments against this Th1/Th2 counter-regulation model: both 
allergies and helminth infections are characterized by induction of Th2-polarized immune 
response and IgE, however in tropical countries with high prevalence of Th2-driving helminth 
infections, allergies are less common (ISAAC 1998). Moreover, the prevalence for 
autoimmune diseases like type 1 diabetes, multiple sclerosis or Crohn’s disease (all with a 
Th1-biased inflammatory response) is increasing parallel to asthma incidences (Bach 2002). 
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2.3. Worms and allergy 
A hypothesis, attempting to reconcile all these observations, is that the primary consequence 
of all pathogen infections is the induction of immunoregulatory mediators critical for the 
prevention of immune hyperreactivity (allergy and autoimmunity) (Wills-Karp 2001).  
Over the last years there have been multiple reports about the correlation between worm 
infections and allergic disorders in human studies (Dagoye 2003, van den Biggelaar 2001, 
2004, Araujo 2006). Studies on helminths revealed links between the suppression of allergic 
hyperreactivity and its reversal through treatment with anti-helminthics (Lynch 1993, van den 
Biggelaar 2004), and various immunological parameters to explain this phenomena were 
evaluated (e.g. for Schistosoma: van den Biggelaar 2000; Araujo 2004). Nevertheless, there 
are also reports indicating an enhancement of allergic inflammation in humans infected with 
Ascaris lumbricoides and Anisakis simplex (Kennedy 2000, Obihara 2006). More recent 
human studies indicate that worm infection has protective effects on asthma, but detrimental 
effects on dermatitis (Haileamlak 2005). Metaanalysis of recent publications were carried out 
by Leonardi-Bee and colleagues and they came to the conclusion that Ascaris infections 
appear to increase incidence of asthma, whereas hookworm infestations seem to reduce 
incidences of asthma (Leonardi-Bee 2006). 
As human studies have not always been consistent, a lot of studies have been done in animal 
models: amelioration of allergic asthma was found in infections with gut nematodes, male 
schistosomes and other helminths (Wilson 2005, Kitagaki 2006, Wohlleben 2004, Mangan, 
2004, 2006) and effects on food allergy have also been reported (Nagler-Anderson 2006). A 
protective mechanism of H. polygyrus on allergic hyperreactivity has been shown to be 
dependent on CD25+CD4+ T cells in mesenteric (Wilson 2005) and peribronchial lymph 
nodes (Kitagaki 2006). Also, infection with Strongyloides stercoralis was found to suppress 
pulmonary allergic response in a preventive approach. Although not reducing eosinophilia in 
lungs, OVA-IgE levels were abolished and eotaxin levels strongly decreased (Wang 2001). 
Lately, infection with Trichinella spiralis was linked to inhibition of cellular recruitment to 
lungs of mice infected with influenza A, thereby reducing lung pathology, mostly due to  
TNF- inhibition and not to expansion of IL-10 producing cell populations (Furze 2006). On 
the other hand, Schistosomes protect mice from anaphylaxis by IL-10-producing B cells 
(Mangan 2004) and protection of airway hyper-responsiveness by male schistosomes was 
correlated to increased IL-10 levels in lungs (Mangan 2006). H. polygyrus´ dampening of 
food allergy caused by peanut is thought to be mediated via an IL-10-dependent regulatory 
mechanism (Bashir 2002). This protection could be transferred by CD4+ T cells harvested 
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from worm-infected MLN and spleens (Nagler-Anderson 2006). In addition, an influence on 
co-stimulatory molecules on APCs was reported (upregulation of CD80 and CD86), but only 
locally in the mucosa (Peyers patch and MLN) and not in the periphery (spleen). Moreover, 
suppression of allergen-induced airway inflammation by Nippostrongylus brasiliensis was not 
observed in IL-10-deficient mice (Wohlleben 2004). Within Ascaris infection, transfer of 
regulatory T cells of infected animals was capable of mediating amelioration of allergic eye 
disease (Schopf 2005). Somewhat conflicting results were observed when rats were infected 
with Strongyloides venezuelensis, concomitant with induction of airway inflammation. 
Negrao-Correa and co-workers reported prolonged pulmonary inflammation, but suppressed 
AHR during lung passage of the parasite, indicating a partial protective effect of worm 
infection (Negrao-Correa 2003).  
Intensity and chronic nature of infection seem to be very important factors that are associated 
with amelioration of allergic inflammation. Whereas, in great contrast, acute infections with 
low worm burdens may procure devastation or aggravation of allergic responses (Smits 2007). 
It also seems to be crucial as to which parasite infects the patient/animal and which disease is 
monitored, as e.g. a study in Ethiopia revealed reduced wheeze with hookworm infection but 
increased allergen skin test reactivity with trichuriasis (Scrivener 2001). 
In summary parasitic worm infections characteristically elicit Th2-polarized responses quite 
similar to atopic individuals. However, allergies seem to be less prevalent in helminth infected 
people. Parasites which can exploit host down-regulatory networks are likely to gain 
advantage in the battle for long-term survival in the host (Maizels 2003). The immune system 
may have evolved optimally in the regulated environment of infections, but now that the 
environment has become more hygienic sufferers might be prone to overzealous reactions to 
innocuous substances, generating the rapidly increasing levels of allergy and autoimmunity 
being experienced in the developed world (Wilson 2005).  
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Figure 1: Helminth infections induce a Th2 response, partly because they harbour Th2 driving molecules 
(nematode allergen, small triangle). In a protective host response (upper panel) the cytokines interleukin-4  
(IL-4), IL-5 and IL-13 are secreted, which lead to eosinophilia and production of allergy-associated IgE 
antibodies by B cells. Mediators released by activated eosinophils and mast cells kill opsonised larval stages. 
Successful helminths are able to evade the host’s protective immune response (base panel). Parasite 
immunomodulators may induce regulatory T cells (Treg), immunosuppressive cytokines (IL-10, TGF-ß) and 
switching to competing IgG4 antibodies that do not activate eosinophils. Thereby killing of larvae is anticipated. 
Allergic immune responses resemble host protective immune responses regarding Th2 polarization, IgE, mast 
cells and eosinophilia. Blocking of these mechanisms does not only protect larvae but may also control 
inflammation and allergy. 
Down-modulation of allergic inflammation has been explained as a survival strategy of 
worms. Well-adapted parasites can prevent the triggering of allergic effector mechanisms in 
order to modulate inflammatory host responses directed against them (Moncayo 2006). Figure 
1 shows an overview of the interplay of host protective and parasite-induced evasion 
mechanisms.  
As a side effect, worm-induced immune modulation can lead to down-regulation of other 
immune responses, such as allergic reactions in humans and experimental animals 
(Yazdanbakhsh 2002, Wilson 2005, Dunne 2005, Fallon 2007), and also of viral and bacterial 
infections (Fox 2000, Furze 2006).  
2.4. The filarial cystatin Av17 
Immunomodulatory effects of parasitic worms can be exerted by secreted compounds, which 
have supposedly been shaped and optimized during co-evolution with their vertebrate hosts. 
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Strong candidates for the immunomodulatoy components are parasite cystatins (Hartmann 
2003, Maizels 2004).  
Cystatin of the filaria Acanthocheilonema viteae is secreted by all developmental stages 
(Hartmann 1997) and can be found in excretory/secretory (E/S) products of worms in culture. 
As the larvae are found in blood and adult worms dwell in tissue the filarial parasite and the 
secreted cystatins can get in direct contact with the host’s immune system.  
A B 
Figure 2: Acanthocheilonema viteae cystatin (Av17): (A) computer-generated model of A. viteae cystatin 
(generated by T. Buhrke) showing relevant region for its proteinase inhibitor function. (B) mechanistic model of 
interaction of Av17 with a protease and the protease-inhibitor complex. Letters indicate highly conserved regions 
binding into the active site of the protease.  
Filarial cystatin belongs to the cystatin super-family that consists of three major families of 
evolutionary related, reversible tight-binding inhibitors of cysteine proteases (Nicklin 1984). 
Type I cystatins, the stefins, are unglycosylated proteins of about 11 kDa which lack a signal 
sequence and any disulphide bonds, and are predominately intracellular. Type II cystatins, the 
second family, are about 13–14 kDa in size, contain a signal sequence and two carboxy-
terminal disulphide bonds and are usually exported from the cell. Type III cystatins, the 
kininogens, are glycosylated, multifunctional proteins with three cystatin domains that contain 
disulphide bonds and are synthesized in the liver and exported into the blood. They are the 
major inhibitors of cysteine proteinases there, along with alpha-2-macroglobulin (Barrett 
1986, Abrahamson 1994).  
Cystatins are found in all living organisms and regulate cysteine proteases which are involved 
in many biological processes, such as protein metabolism, antigen-processing and 
inflammation (Henskens 1996). Cysteine proteases are defined as enzymes that degrade 
polypeptides. Cysteine proteases have a common catalytic mechanism that involves 
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nucleophilic cysteine thiol in a catalytic triade. Examples for cysteine proteases are papain, 
cathepsins, caspases and calpains. (en.wikipedia.org/wiki/Cysteine_protease). Cysteine 
proteases degrade proteins within the endolysosomal compartment of APCs. Furthermore, 
they are involved in the cleavage of the MHC class II-associated invariant chain, which leads 
to the formation of class II –associated invariant chain peptide (CLIP)-associated MHC 
molecules. By removing CLIP, the binding of peptides to MHC class II is possible (Watts 
2001). 
Acanthocheilonema viteae cystatin (model of the structure in Figure 2A) exhibits highest 
homology to the type 2 family cystatins. Its close relative, human cystatin C, is expressed and 
secreted constitutively by mononuclear phagocytes (Warfel 1987). Among others, the 
cystatins have important functions in the regulation of proteases relevant in immune 
responses. Thus, the endogenous inhibitor cystatin C influences the fate of newly synthesized 
peptide-MHC class II complexes by regulating the activity of cathepsin S, a cysteine protease 
that is essential in Ii-chain degradation in B cells and dendritic cells (Riese 1996, Pierre 1998, 
Nakagawa 1999). Additionally, human cystatin C has been described to inhibit the phagocytic 
function of monocytes and granulocytes (Leung-Tack 1990 a, b), and it has been shown that 
various members of the cystatin super-family up-regulate the inducible NO production of 
murine macrophages (Verdot 1999).  
Schoenemeyer and colleagues were able to show that a cystatin secreted by the human filariae 
Onchocerca volvolus is also able to inhibit human cysteine proteases. The immunologically 
relevant cathepsins L and S were significantly down-modulated by O. volvolus cystatin 
(Schoenemeyer 2001) thereby altering antigen presentation of APCs (model of the interaction 
shown in Figure 2B). Furthermore in vitro studies on recombinant O. volvolus and A. viteae 
cystatin revealed that stimulation of human PBMCs or murine splenocytes led to secretion of 
high amounts of IL-10 and inhibition of T cell proliferation (Hartmann 2003). The effect was 
specific for recombinant cystatin of filarial nematodes, whereas recombinant cystatin of the 
free-living nematode Caenorhabditis elegans did not modulate macrophage functions in vitro 
(Schierack 2003). Cystatins of several species have been investigated (Onchocystatin in 
Onchocerca volvolus, Lustigmann 1992; Nippocystatin in Nippostrongylus brasiliensis, 
Dainichi 2001; Litomosoides sigmodontis cystatin, Pfaff 2002) and are seen to be associated 
with immunosuppression. The most information is known about Av17 and Ov17. 
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2.5. Allergic disorders 
Allergic disorders like asthma, rhinitis and atopic dermatitis, affect 10 – 15 % of Western 
populations and their prevalence has doubled in the last 10-15 years (Kay 2001). Interestingly, 
in the past decades the frequency and severity of atopic disorders have steadily increased, 
particularly in developing countries (Braman 2006). 
These diseases are caused by a dysregulated immune response and share a common etiology, 
in that the immune system is misguided and treats foreign antigens as allegedly harmful 
agents. Allergic disorders lead to production of IgE against harmless environmental antigens 
like pollen, animal proteins or house dust mites, and the induction of eosinophilia. A strong 
bias to a Th2-biased immune response, which is thought to be caused by a lack of danger 
signals mediating Th1 responses and uptake of allergens via mucosal surfaces, is thought to 
be the main reason for pathology (Umetsu 2006 a, b).  
Asthma belongs to type I (immediate) hypersensitivity responses. Type I responses occur in 
two phases, the immediate reaction after a few minutes which is characterized by 
vasodilation, congestion and edema (mainly mediated by IgE and basophils) and the late 
phase. The late phase occurs after some hours and is characterized by an influx of neutrophils, 
eosinophils and Th2 lymphocytes into the airways (Effros 2007).  
Bronchial asthma is a chronic inflammatory airway disease that is defined by reversible 
airway obstructions and non-specific airway hyper-responsiveness (AHR) (Umetsu 2002).  
It is generally accepted that pathological changes in asthma are induced by a chronic 
inflammatory process which is characterized by infiltration of lymphocytes and eosinophils 
into bronchial mucosa, increased mucus production and submucosal edema (Hamelmann 
2001). 
Activated Th2 cells in an atopic individual secrete IL-4, IL-5, IL-9 and IL-13. The increase in 
IL-2, IL-4 and IL-13 stimulates the production of IgE by B lymphocytes (plasma cells). IgE 
can bind tightly to FcR1 receptors on mast cells which release vasoactive amines and 
cytokines when antigens crosslink these bound IgE molecules. Class switches to IgE cannot 
occur without IL-4 or IL-13. IL-5 is a so-called hematopoetic cytokine that stimulates 
eosinophil production in the bone marrow as well as activation and chemotaxis of eosinophils 
and basophils (Simon 1999). Eosinophils can bind to IgE opsonized surfaces and may secrete 
major basic and major cationic proteins which can damage lung surfaces (or damage the 
tough cuticula of helminths) (Effros 2007). IL-9 seems to exert effects on production, 
activation and chemotaxis regarding mast cells (Renauld 1995, Godfraind 1998). 
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Within allergic disorders, atopic dermatitis (A.D.) is described as a chronic inflammatory 
disease of the skin associated with cutaneous hyperreactivity (Leung 2003). The concept of 
the pathobiology of atopic dermatitis involves a systemic Th2 response, in addition to a 
biphasic T cell response in the skin, with Th2 cells in acute A.D. and Th1 cells in the chronic 
phase. Atopic dermatitis involves complex interactions between resident and infiltrating cells 
influenced by a variety of proinflammatory cytokines and chemokines (Leung 2004).  
In contrast, allergic airway hyperreactivity is a chronic disease in which continuously strong 
Th2 inflammatory responses are induced leading to recruitment of inflammatory cells into the 
lung and pathological changes of the lung tissues (Umetsu 2002). Type 2 mediated 
inflammation is characterized by extensive mast cell degranulation and invasion of 
eosinophils and basophils into the tissue. 
Instead of preventing allergies by avoiding risk factors, recent studies try the reverse 
approach. The idea is to facilitate exposure to protecting factors which may promote induction 
of immunological tolerance against harmless antigens. In other words the strategy is shifting 
from allergy prevention by avoidance to tolerance induction (Hamelmann 2008). 
Apart from specific immunotherapy (SIT), also application of food-borne microbes and even 
helminths and their components might be promising candidates.  
With all the knowledge available about suppressive capacities of the single recombinant 
helminth protein Av17 in vitro, this study should evaluate if Av17 would be able to modulate 
two models of allergic disease, namely allergic asthma and atopic dermatitis. Furthermore, 
gastrointestinal (GI) worm infection should be evaluated in both models, yielding information 
as to whether or not GI nematode induced immunomodulation is restricted to mucosa-
associated disease. 
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3. Results 
3.1. Av17 and Allergic Airway Hyperreactivity (AHR) – a murine asthma model to 
       reveal in vivo effects 
3.1.1. Application of filarial cystatin blocks allergic airway disease in a preventive and a 
          pre-challenge approach 
In order to study immunomodulatory effects of filarial cystatin (Av17) in vivo, Av17 was 
applied in a murine model for human allergic asthma, namely in the murine model of 
ovalbumin (OVA) - induced allergic airway hyperreactivity. To induce allergic airway 
inflammation mice were sensitized twice with the model allergen OVA and subsequently 
challenged with OVA via the airways.  
The capacity of cystatin to alter inflammation was tested in two different settings: the 
preventive and the pre-challenge approach. For preventive treatment BALB/c mice were 
injected intraperitoneally with doses of 20μg E. coli-expressed recombinant cystatin from 
Acanthocheilonema viteae (Av17) 4 times in weekly intervals. The preventive treatment 
provides the possibility to interfere with sensitization right from the start: The parasite protein 
was applied during sensitization together with the first OVA treatment (Fig. 3A). In contrast, 
pre-challenge treatment with Av17 reveals modulation of inflammation after the sensitization 
phase with the allergen is completed. Three 20 μg doses of cystatin were applied after the 
sensitization phase with OVA but before intranasal allergen challenge (Fig. 3B). 
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FIGURE 3: Scheme of (A) the preventive and (B) the pre-challenge model of airway hyperreactivity (AHR). 
Intraperitoneal applications of ovalbumin (OVA) or filarial cystatin (Av17) are indicated by i.p., intranasal 
ovalbumin challenge is indicated by i.n.  
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3.1.2. Filarial cystatin inhibits the development of allergic airway hyperresponsiveness 
           in preventive and pre-challenge setting 
Both approaches tested revealed a strong suppression of allergic inflammation in the 
experimental animals. This was reflected by a downmodulation of hallmarks of murine airway 
inflammation.  
First, significantly reduced total numbers of cells (p < 0.028 prev, p < 0.02 pre) in 
bronchoalveolar lavage fluid (BALF) were observed. Total cell numbers assessed were at the 
level obtained in naïve mice. This effect of cystatin application was most pronounced for 
eosinophils (p < 0.05 prev, p < 0.028 pre), which reflects a strong suppression of the main 
inflammatory cells in the AHR model. Other cell types in BALF did not differ significantly. 
Treatment with the irrelevant E. coli-expressed recombinant control protein DHFR did not 
lead to significant changes in cell numbers or cell types in the BALF (Fig. 4).  
0
40
80
120
160
total cells eosinophils
%
 c
el
ls 
in
 B
A
LF
naive
OVA
OVA/Av17 prev
OVA/DHFR
OVA/Av17 pre
* * * * * *
 
FIGURE 4: Influence of treatment with filarial cystatin (Av17) on total cell numbers and eosinophil numbers in 
the BALF of mice observed in the preventive (prev) and the pre-challenge (pre) model, respectively. naive: PBS-
treated mice; OVA: ovalbumin-treated mice; OVA/Av17: ovalbumin and Av17–treated mice; OVA/DHFR: 
ovalbumin and DHFR (control protein)–treated mice. Representative data of three individual experiments with 
5-6 animals per group; to directly compare data of the pre-challenge with the preventive model data is expressed 
in percentages (OVA-group is 100%); *p < 0.05. 
Second, histological analysis of the lung alveolar tissue revealed clear differences between 
cystatin-treated animals and controls. Only background levels of inflammatory cell infiltration 
within the lung tissue were observed in hematoxylin/eosin stainings of bronchiole regions of 
lungs in the preventive model. Furthermore mucus production by goblet cells was found to be 
nearly absent in mice co-treated with OVA/cystatin but dramatically increased in OVA-
controls, as indicated by PAS/H staining for mucin (Fig. 5). 
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Naive         OVA                  OVA/Av17 
FIGURE 5: Representative lung sections of Av17-treated mice in the preventive model. Lung sections are 
stained with PAS/H for analysis of mucus production (red). Increased cell infiltration is indicated in blue (nuclei, 
he staining). Magnification 400x, histology was performed by Dr. W. Bleiß und A. Marko. naive: PBS-treated 
mice; OVA: ovalbumin-treated mice; OVA/Av17: ovalbumin and Av17–treatment. 
Third, cystatin treatment significantly inhibited the development of in vivo airway 
hyperreactivity (AHR) in treated mice in the preventive (p < 0.028) (Fig. 6A) as well as in the 
pre-challenge model (p < 0.028, Fig. 6B). This was indicated by reduced Penh values (Pause 
enhanced) assessed by whole body plectysmography. Animals co-treated with cystatin and 
OVA developed less bronchoconstriction in response to increasing metacholin concentrations 
and therefore had shorter “breaks” (Penh) in breathing.  
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FIGURE 6: Measurement of airway hyperreactivity (AHR) after application of different dosages of 
methacholine (MCh) to mice treated with filarial cystatin (Av17) (A) in the preventive (prev) and (B) in the pre-
challenge (pre) model. AHR is diplayed by Penh (pause enhanced) values. naive: PBS-treated mice; OVA: 
ovalbumin-treated mice; OVA/Av17: ovalbumin and Av17–treatment. Representative data of two individual 
experiments with 5-6 animals per group. *p < 0.05. 
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Another typical feature of allergic asthma is the production of allergen-specific antibodies and 
antibodies of the subclass IgE. Treatment with cystatin significantly reduced serum levels of 
total IgE (p < 0.0003, Fig. 7A) as well as of OVA-specific IgE (p < 0.0002, Fig. 7B) when 
applied in the preventive model. This effect was specific to IgE, as serum levels of OVA-
specific IgG1 and IgG2a were not significantly altered compared to sensitized and challenged 
controls (Fig. 7C, D).  
A
FIGURE 7: Effects of preventive (prev) and pre-challenge (pre) application of filarial cystatin on sensitization 
were analyzed by measurement of (A) total IgE, (B) OVA-specific IgE, (C) OVA-specific IgG1 and (D) OVA-
specific IgG2a concentrations in sera. naive: PBS-treated; OVA: ovalbumin-treated; OVA/Av17: ovalbumin and 
Av17–treated; OVA/DHFR: ovalbumin and DHFR–treated mice. To directly compare data of the pre-challenge 
with the preventive model data are expressed in percentages (OVA-group is 100%); Representative data of three 
individual experiments with 5-6 animals per group. *p < 0.05, **p< 0.005. 
Cystatin application in the pre-challenge model resulted in significantly decreased OVA-IgE 
levels (p < 0.02; Fig. 7B), whereas total IgE production showed only a trend towards down-
regulation (Fig. 7A). Hence, in the pre-challenge model cystatin is able to inhibit levels of 
OVA-specific IgE production following intranasal challenge, whereas amounts of OVA-IgE 
produced in response to sensitization remain unaffected. OVA – IgG1 and OVA – IgG2a were 
not altered. 
The significant inhibition of IgE production in the preventive model was accompanied by a 
reduced capacity of sera from cystatin/OVA-treated mice to induce degranulation of 
basophils. In the RBL-test cells were sensitized with test sera and crosslinking of bound IgE 
was stimulated with 5μg/ml OVA. OVA/Av17 - treated mice released significantly lower 
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amounts of the mediator ß-hexosaminidase (15 %, p < 0.009) in the preventive approach. This 
means that less RBL cells degranulated because there was less crosslinking to induce 
degranulation and less OVA-specific IgE. Interestingly, crosslinking and degranulation 
effectivity seemed to be downmodulated in pre-challenge approach as well, indicated by 
reduced ß-hexosaminidase release, although this did not reach statistical significance (Fig. 8). 
Of interest, no Av17-specific IgE could be measured via RBL test and ELISA (data not 
shown). 
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FIGURE 8: Functional OVA-specific IgE was tested in RBL (rat basophil leukemia cell) assay. Degranulation 
of cells is shown by percentage of mediator release. naive: PBS-treated mice; OVA: ovalbumin-treated mice; 
OVA/Av17: ovalbumin and Av17–treatment in preventive (prev) and pre-challenge (pre) approach. 
Representative data of three individual experiments with 5-6 animals per group. **p < 0.005. 
Together, these data suggest that cystatin interferes with the recruitment of inflammatory cells 
to the lung, airway hyperresponsiveness, mucus production in lungs and with allergen-specific 
IgE production, thus inhibiting the main features of allergen-induced alterations in this mouse 
model both when applied during and after sensitization. 
3.1.3. Filarial cystatin alters cytokine levels 
Regarding cytokine patterns the focus was on systemic and local alterations, meaning 
cytokine levels in splenocyte cultures and BAL-fluid (BALF). Mice treated with 
OVA/cystatin contained clearly less IL-4 in BALF as animals treated with OVA only (p < 
0.02), or with OVA/DHFR (p < 0.028).  
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FIGURE 9: Influence of preventive (prev) and pre-challenge (pre) treatment with filarial cystatin on IL-4 levels 
in bronchoalveolar lavage fluid (BALF) and in splenocytes stimulated with OVA . naive: PBS-treated; OVA: 
ovalbumin-treated; OVA/Av17: ovalbumin and Av17–treated; OVA/DHFR: ovalbumin and DHFR–treated 
mice. Representative data of three individual experiments with 5-6 animals per group. *p < 0.05., **p < 0.005 
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The reduction in this typical Th2 cytokine that is associated with antibody subclass switching 
to IgE, was significant both in the preventive and in the pre-challenge model (Fig. 9). Along 
with the local change in BALF, splenocyte cultures of OVA/cystatin-treated mice too, 
produced significantly less IL-4 in response to allergen stimulation compared to controls in 
both models (p < 0.0004 prev, p < 0.015 pre, Fig. 9) accounting for a systemic cystatin effect. 
Although the levels of IL-10, a strongly anti-inflammatory Th2 cytokine, in BALF were 
similar between the groups, IL-10 production by spleen cells stimulated with cystatin ex vivo 
was significantly increased in the preventive model (p < 0.01) and even more pronounced in 
the pre-challenge model (p < 0.002 compared to OVA, p < 0.028 compared to Av17 prev, 
Fig. 10). 
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FIGURE 10: Induction of IL-10 production in splenocytes after stimulation with Av17 in the preventive (prev) 
and pre-challenge (pre) model. naive: PBS-treated; OVA: OVA-treated mice; OVA/Av17: ovalbumin and filarial 
cystatin–treated mice. Representative data of 3 individual experiments with 4-6 animals are shown; *p < 0.05; 
**p < 0.005. 
In several experiments cytokine bead arrays were performed to gain further information on 
cytokines such as eosinophilia-associated IL-5 and mucus-associated IL-13 as well as the Th1 
cytokines IL-12, IFN- and TNF-. They were analysed in BALF and in culture supernatant 
of OVA-stimulated spleen cells (Tab. 1). Both IL-5 and IL-13 levels showed a trend towards 
reduction at the site of inflammation, in BALF, though the differences did not reach statistical 
significance. The Th1 cytokines showed similar or slightly decreased amounts in BALF 
compared to the OVA-group but again none of these changes was significant. Regarding 
systemic production, both IL-5 and IL-13 levels were elevated similarly to OVA-group, 
indicating that only parts of the overall Th2-response to OVA were altered systemically by 
cystatin. However, it could be excluded that the protective effect of Av17 treatment was a 
mere switch to a Th1-response, because none of the measured Th1 cytokines was elevated in 
OVA-stimulated splenocytes of cystatin treated animals. Also stimulation with Av17 did not 
lead to cytokine production other than IL-10. 
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naive OVA OVA/Av17 BALF (pg/ml) 
IL-5 48 +/- 9 315 +/- 17 189 +/- 49 
IL-13 174 +/- 74 453 +/- 20 273 +/- 48 
IFN- 22 +/- 7 38 +/- 17 15 +/- 0,1 
TNF 63 +/- 9 76 +/- 13 54 +/- 0,1 
IL-12p40 30 +/- 3 90 +/- 44 48 +/- 8 
 
naive OVA OVA/Av17 spleen (pg/ml) 
IL-5 529 +/- 132 2746 +/- 45 2833 +/- 162 
IL-13 1280 +/- 612 2676 +/- 806 2578 +/- 469 
IFN- 2826 +/- 450 85 +/- 32 154 +/- 133 
TNF 127 +/- 36 278 +/- 6 284 +/- 10 
IL12p40 315 +/- 11 87 +/- 28 150 +/- 8 
Table 1: Cytokine levels determined in bronchoalveolar lavage fluid (BALF) and in OVA-stimulated 
splenocytes by cytokine bead array. Th2 cytokines IL-5 and IL-13 as well as Th1 cytokines IFN-, TNF and IL-
12p40 from an individual experiment with 5 animals per group in the pre-challenge setting is shown. Naïve: 
PBS-treated animals, OVA: ovalbumin-treated animals, OVA/Av17: ovalbumin and filarial cystatin-treated 
animals. 
TGF-ß values were assessed in BALF and determined by real-time PCR in mRNA of lung 
tissue but again showed a trend towards reduction but no significant alteration in mice treated 
with cystatin compared to controls (data not shown). Finally proliferation of spleen cells in 
response to OVA was monitored to rule out mere anergy of splenocytes resulting in lower 
cytokine levels. However, proliferation was never significantly altered in cystatin-treated 
animals compared to control groups (data not shown). 
These data are compatible with a strong down-regulation of effector functions of the allergic 
immune reaction by filarial cystatin, resulting in abrogation of allergic sensitization and 
impaired Th2 immune responses, reduced eosinophilic airway inflammation and decreased 
airway hyperreactivity.  
3.1.4. Filarial cystatin targets macrophages  
In previous studies, it was shown that filarial cystatin targets and alters macrophages in vitro 
(Hartmann 1997) leading to IL-10 production and T cell suppression. Therefore, the relevance 
of macrophages in the mouse model of OVA-induced airway inflammation was investigated. 
Macrophages were selectively depleted in vivo by use of clodronate containing liposomes 
(MLV) (van Roijen 1994). These multilamellar vesicles are made of lipids selecting for 
uptake by macrophages. In addition the chemical is not phagocytosed when “free” outside the 
vesicles, preventing unspecific killing of phagocytes by release of clodronate of killed 
macrophages. Clodronate MLVs were applied intraperitoneally and intranasally two days 
prior to airway allergen challenges of sensitized and treated mice. This treatment led to the 
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loss of > 95% of macrophages in the BALF and in the peritoneum, as confirmed by FACS 
staining of cells positive for the macrophage marker F4/80 and negative for the B cell marker 
CD19 and the T cell marker CD3 (Fig. 11). Additional analyses confirmed that macrophages 
remained absent for at least 6 days (data not shown). 
FIGURE 11: Depletion of macrophages is achieved by application of multilamellar vesicles (MLV) filled with 
the chemical clodronate. Schematic view of MLV and representative FACS plot of peritoneal excudate cells 
(PEC) 4 days after application: Cells are gated for no expression of T cell marker CD3 (CD3-) and B cell marker 
CD19 (CD19-). Macrophages are identified by expression of the marker F4/80. naïve (red): no MLV-application, 
treated (blue): application of MLV in Av17-treated animals.  
To rule out effects of macrophage depletion on the model OVA-treated mice were depleted of 
macrophages in a preliminary test. Depletion of macrophages neither prevented nor enhanced 
the onset of the allergic airway inflammation, indicated by the absence of significant changes 
on the cell recruitment into the lung within the OVA-group (Fig. 12). In contrast, in cystatin-
treated animals the depletion of macrophages led to a reversion of the total cell numbers (p < 
0.008) and eosinophils (p < 0.002) in BALF to the level of the OVA-sensitized and 
challenged control group (Fig. 12). 
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FIGURE 12: Effects of filarial cystatin are dependent on macrophages. Shown are the total cell numbers and 
eosinophil numbers in BALF in mice depleted of macrophages in the preventive cystatin-treatment approach. 
naive: PBS-treated mice; OVA: ovalbumin-treated mice; OVA/MLV: ovalbumin and MLV-treated mice; 
OVA/Av17: ovalbumin and filarial cystatin (Av17)-treated mice; OVA/Av17/MLV: ovalbumin and Av17-
treated mice depleted of macrophages by MLV; Representative data of three individual experiments with 5-6 
animals per group **p < 0.005 
Interestingly, the treatment with multilamellar vesicles filled with clodronate also 
significantly elevated the production of total IgE (p < 0.05, Fig. 13A) and of OVA-specific 
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IgE in sera of OVA/cystatin–treated mice (p < 0.007; Fig. 13B). However, antibody levels 
were still lowered in comparison to OVA-control group. 
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FIGURE 13: Influence of macrophage depletion on (A) total IgE and (B) OVA-specific IgE levels in sera of 
treated mice (preventive approach). naive: PBS-treated mice; OVA: ovalbumin-treated mice; OVA/MLV: 
ovalbumin and MLV-treated mice; OVA/Av17: ovalbumin and filarial cystatin (Av17)-treated mice; 
OVA/Av17/MLV: ovalbumin and Av17-treated mice depleted of macrophages by MLV; IgE values are 
expressed in percentages (OVA = 100%). Representative data of three individual experiments with 5-6 animals 
per group. *p < 0.05;**p < 0.005. 
OVA-specific IL-4 production of restimulated spleen cells was not significantly altered by 
macrophage depletion, although a trend towards upregulation could be observed (Fig. 14A). 
However, AHR of macrophage-depleted, OVA/cystatin–treated mice rose significantly (p < 
0.04) (Fig. 14B). 
Interestingly, macrophage depletion had a drastic effect on IL-10 production of splenocytes. 
Lack of macrophages resulted in a significant decrease of IL-10 production in Av17-
stimulated cultures indicating an important role for macrophages in Av17-specific IL-10 
production (Fig. 14C).  
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FIGURE 14: Effects of macrophage depletion on (A) OVA-specific IL-4 production of spleen cells and (B) 
airway hyperreactivity of mice after treatment with different dosages methacholine (MCh). (C) Av17-specific 
IL-10 production in splenocytes. Naive: PBS-treated mice; OVA: ovalbumin-treated mice; OVA/Av17: 
ovalbumin and filarial cystatin (Av17)-treated mice; OVA/Av17/MLV: ovalbumin and Av17-treated mice 
depleted of macrophages; Penh: pause enhanced, Representative data of three individual experiments with 5-6 
animals per group.*p < 0.05. 
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Together, these results indicate that macrophages translate the immunomodulatory effects of 
cystatin airway inflammation, airway hyperreactivity and IgE production and are strongly 
involved in IL-10 production.  
3.1.5. Cystatin increases the number of regulatory T cells 
As T regulatory cells have been described to play an important role in allergy and asthma 
(Hawrylowicz 2005a) we aimed to determine whether cystatin treatment had an influence on 
the numbers of Treg cells at the site of inflammation. Hence, we analyzed the co-expression 
of the surface markers CD4, CD25 and CD103 on peribronchial lymph node cells (PBLNC). 
The proportion of Treg cells was significantly elevated in OVA/cystatin-treated animals as 
compared to OVA-controls (3% versus 1.9%, p < 0.05) and to OVA/DHFR-controls (3% 
versus 2.1%; p < 0.05; Fig. 15). 
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FIGURE 15: Treatment of mice with filarial cystatin in the preventive approach alters Treg numbers. Shown are 
(A) FACS plots of PBLN cells of one representative animal per group and (B) numbers of Treg cells 
(CD4+CD25+CD103+) in PBLN as mean of groups; naïve: PBS-treated mice; OVA: ovalbumin-treated mice; 
OVA/Av17: ovalbumin and (Av17)-treated mice, OVA/DHFR: ovalbumin and DHFR–treated mice; 
Representative data of three individual experiments with 5-6 animals per group *p<0.05 
To corroborate the identification of Treg cells, in several experiments the transcription factor 
forkhead box transcription factor p3 (Foxp3), which is regarded as one of the most reliable 
Treg markers at the moment, was stained in addition to the cell surface markers. More than 
96% of the Treg cells expressed Foxp3 (Fig. 16A) verifying the analyses. 
FIGURE 16: (A) Representative histograms of Foxp3+ cells in CD4+CD25+CD103+ positive PBLNC. 
Histograms are representative for all animals in all groups. OVA: ovalbumin-treated mice; OVA/Av17: 
ovalbumin and Av17-treated mice. (B) Verification of Treg - depletion effectivity. Shown are representative 
plots of CD4/CD25 gated PBLN (peribronchial lymph node cells) without (left) and after (right) CD25Ab 
(PC61) treatment. Naïve: no PC61 treatment, + PC61: after application of CD25Ab 
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In order to analyze the role of Treg cells in cystatin-induced immunomodulation sensitized 
animals were treated with anti-CD25 antibodies five days prior to the first airway allergen 
challenge. Application of PC61 (CD25Ab) significantly decreased the number of 
CD4+CD25+CD103+ Treg cells to 0.16% in PBLNC (Fig. 16B).  
Analysis of cell numbers and types in BALF of cystatin treated mice with depleted Treg cells 
was performed: The levels of total cells as well as eosinophils showed a trend of restoration 
though this did not reach statistical significance (Fig. 17). Application of isotype-matched 
control antibodies did not alter cystatin effects on BALF cells. 
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FIGURE 17: Depletion of CD25-positive cells partly reversed the immunomodulation exerted by prevetive 
treatment with filarial cystatin. Shown are alterations in total cell and eosinophil numbers in BALF. naive: PBS-
treated mice; OVA: ovalbumin-treated mice; OVA/Av17: ovalbumin and filarial cystatin (Av17)-treated mice; 
OVA/Av17/rat IgG: mice treated with OVA and Av17 plus isotype-matched control antibodies, 
OVA/Av17/CD25: OVA and Av17-treated mice depleted of Treg cells by application of CD25 antibodies, 
Representative data of 3 individual experiments with 4 animals per group. *p < 0.05. 
However, the production of total IgE (p < 0.002; Fig. 18A) and OVA-specific IgE (p < 0.002; 
Fig. 18B) was significantly restored compared to cystatin treated animals with non-
manipulated Treg cells. 
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FIGURE 18: Depletion of Tregs in filarial cystatin-treated (Av17) mice in the preventive model affects levels of 
(A) total and (B) OVA-specific serum IgE; naive: PBS-treated mice; OVA: ovalbumin-treated mice; 
OVA/Av17: OVA and (Av17)-treated mice; OVA/Av17/CD25: OVA and Av17-treated mice depleted of 
Tregs, IgE-values are expressed in percentages (OVA-group is 100%); Representative data of 3 individual 
experiments with 4 animals per group *p < 0.05, **p < 0.005. 
Anyhow, no changes were determined for allergen-specific IL-4 production (Fig. 19A) and 
development of AHR in cystatin-treated mice after depletion of Treg cells (Fig. 19B).  
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FIGURE 19: Effect of depleting Tregs in Av17 preventive model on (A) OVA-specific IL-4 production in 
spleen and on (B) airway hyperreactivity in response to increasing metacholine (MCh) concentrations. naive: 
PBS-treated mice; OVA: ovalbumin-treated mice; OVA/Av17: OVA and filarial cystatin (Av17)-treated mice; 
OVA/Av17/aCD25: OVA and Av17-treated mice depleted of Tregs. Representative data of 3 individual 
experiments with 4 animals per group. *p < 0.05. 
These data indicate that Treg cells are involved in the cystatin-induced effects on murine 
airway hyperreactivity, albeit to a less prominent degree than macrophages.  
3.1.6. Inhibition of allergic responses by cystatin is dependent on IL-10 
When addressing the question of possible mediators for the protective effect of cystatin in the 
murine asthma model IL-10 seems to be a striking candidate for several reasons. First, as 
mentioned above, previous in vitro studies had shown that cystatin is able to induce the 
production of anti-inflammatory IL-10 by macrophages. Second, the depletion of 
macrophages in vivo reversed the effects of cystatin in the asthma model. And third, IL-10 
production was profoundly inhibited in animals lacking macrophages and not being protected 
from asthma (Fig. 14C). Therefore it was hypothesized that IL-10 might be a key mediator of 
cystatin-induced immunomodulation. To analyze its influence, antagonizing anti-IL-10 
receptor antibodies (anti-IL-10R Ab) were used in the pre-challenge model of OVA-induced 
airway hyperreactivity. The pre-challenge model was chosen because Av17-specific IL-10 
production in spleen cells was even more pronounced in this approach in comparison to the 
preventive approach (Fig. 10).  
Anti-IL-10R was injected 3 times along with the filarial cystatin after sensitization and prior 
to the first allergen airway challenge with OVA. Blocking of the IL-10R in OVA/cystatin 
treated animals completely abrogated the protective effect of Av17. Total cell numbers in 
BALF were restored to the degree observed in sensitized and challenged positive control 
animals (p < 0.02) (Fig. 20). This effect of blocking IL-10R was most pronounced for the 
eosinophilic airway infiltration (p < 0.02) (Fig. 20).  
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FIGURE 20: Suppression of allergic responses by filarial cystatin is dependent on IL-10. Shown is the effect of 
application of aIL10R Ab to mice in the pre-challenge model on total cell numbers and eosinophil numbers; 
naive: PBS-treated mice; OVA: ovalbumin-treated mice; OVA/aIL-10R: mice treated with OVA and anti-IL-10 
receptor antibodies; OVA/Av17: OVA and filarial cystatin (Av17)–treated mice; OVA/Av17/aIL-10R: mice 
treated with OVA, Av17 and anti-IL-10R-Ab; OVA/Av17/rat IgG: mice treated with OVA, Av17 and isotype-
matched control antibodies. Representative data of 2 individual experiments with 6 animals per group. *p < 0.05. 
Similarly, the development of AHR (p < 0.048) (Fig. 21A), and the production of OVA-
specific IgE were increased to the levels observed in OVA-sensitized and challenged control 
mice (p < 0.03) (Fig. 21B). However, the inhibition of allergen-specific IL-4 production in 
OVA/cystatin treated animals was not altered after application of anti-IL-10R antibodies (Fig. 
21C). Application of isotype matched control antibodies had no effects on the cystatin-
induced parameters as well as application of IL-10R did not alter the values of the OVA 
positive control group. 
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FIGURE 21: Effects of IL10R-Ab application in the pre-challenge filarial cystatin approach on (A) airway 
hyperreactivity, (B) levels of OVA-specific serum IgE and (C) OVA-specific IL-4 production of spleen cells. 
naive: PBS-treated mice; OVA: ovalbumin-treated mice; OVA/Av17: OVA and filarial cystatin (Av17)–treated 
mice; OVA/Av17/aIL-10R: mice treated with ovalbumin, Av17 and anti-IL-10 receptor antibodies; OVA-IgE 
values are expressed in percentages (OVA-group is 100%); Representative data of 2 individual experiments with 
6 animals per group. *p < 0.05 
These data indicate that IL-10 is a key cytokine in filarial cystatin-induced modulation of 
allergic disease, although IL-10 independent mechanisms like the suppression of allergen-
specific IL-4 have to be taken into account too.  
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3.1.7. Macrophages are main producers of Av17-specific IL-10 
Macrophages and Treg cells are both potent sources of IL-10. To unravel which of these cells 
would be primarily responsible for the IL-10 production after treatment with filarial cystatin 
splenocytes of differently treated animals were stimulated with cystatin. Cystatin-treated 
animals showed significantly increased levels of IL-10 in spleen in comparison to OVA-
treated animals (p < 0.002 pre-challenge model; p < 0.01 preventive model, p < 0.024 
comparison of pre-challenge to preventive model; Fig. 10). However, after depletion of 
macrophages, the IL-10 production was significantly decreased in the OVA/cystatin-treated 
animals (p < 0.04; Fig. 22), whereas such an effect was not observed in spleens of animals 
depleted of Treg cells. Treg–depleted mice actually showed a trend of elevated IL-10 values 
(Fig. 22).  
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FIGURE 22: Monitoring IL-10 production in response to Av17 stimulation in spleen cells after depletion of 
macrophages or Tregs in the preventive model; naive: PBS-treated mice; OVA: ovalbumin-treated mice; 
OVA/Av17: OVA and Av17–treated; OVA/Av17/MLV: OVA and Av17-treated mice depleted of macrophages; 
OVA/Av17/aCD25: OVA and Av17-treated mice in which Treg cells were depleted. Representative data of 3 
individual experiments with 4-6 animals per group. *p < 0.05. 
These data underline the pivotal role of macrophages in the cystatin-induced modulation of 
allergic airway inflammation and hyperreactivity.  
3.1.8. Features of Av17 application in vivo outside inflammation settings  
To rule out negative effects of cystatin on healthy individuals and find out more about 
cystatin-dependent effects on the immune system, cystatin was applied 4 times to BALB/c 
mice in weekly intervals (20μg doses) without allergen-sensitization and challenged with 
either the immunomodulator Av17 (Av17ip/Av17in) or the model allergen OVA 
(Av17ip/OVAin) via the airways. Assessment of airway reactivity and Penh values clearly 
ruled out any negative effect of cystatin on these parameters. Penh values of Av17ip/in and 
Av17ip/OVAin groups were on naïve levels or even showing a trend of reduction, regarding 
Av17ip/in group (Fig. 23A).  
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Analyzing cell numbers and cell types in BALF corroborated these data, although intranasal 
challenge with proteins instead of PBS (as in the naïve group) led to influx of small numbers 
of cells. However the influx was far from scenarios found in airway inflammation (Fig. 23B). 
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FIGURE 23: (A) Airway hyperreactivity and (B) cell numbers in animals injected with cystatin but not 
sensitized with ovalbumin. naïve: PBS-treated mice; Av17ip/OVAin: intraperitoneal (ip) injections of Av17 and 
intranasal (in) challenge with ovalbumin (OVA); Av17ip/Av17in: intraperitoneal and intranasal Av17 
application; OVAip/OVAin: comparison values of OVA ip and OVA in treated mice (no Av17). Shown are 
mean values of 5 animals per group. 
Regarding antibody production cystatin application led to the induction of specific antibodies. 
However no Av17-specific IgE was measurable. Mostly the subclasses IgG1 (described as 
competitor to IgE) and IgG/M were detected (Fig. 24). 
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FIGURE 24: Cystatin-specific antibodies in sera of cystatin injected mice. Subclass test for IgG1, IgG2a, 
IgM/IgG and IgE. Serum levels of cystatin-specific antibodies shown as optical densities (O.D.). Naïve: PBS-
treated mice; Av17ip/OVAin: intraperitoneal (ip) injections of Av17 and intranasal (in) challenge with 
ovalbumin (OVA); Av17ip/Av17in: intraperitoneal and intranasal Av17 application; Shown are mean values of 5 
animals per group. 
Regarding the IL-10 inducing effect of cystatin on splenocytes and macrophages found in 
earlier experiments, it was of special interest to survey also peritoneal excudate cells (PECs). 
First, Av17-stimulated IL-10 secretion of PECs derived from naïve and cystatin-treated mice 
were compared. Both naïve and Av17-PEC were found to produce high levels of IL-10 when 
stimulated with cystatin. The Av17-treated PECs produced a little more IL-10 than naïve 
PECs but this was not statistical significant (Fig. 25A). Cystatin-stimulated splenocytes 
produced very low levels of IL-10 in this setting (up to 100pg in comparison to up to 400pg in 
PECs). In addition, IL-10 production was not found in naïve splenocytes, whereas intranasal 
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treatment seemed to enhance production, although this was not statistical significant (Fig. 
25B). These data point to macrophages in PECs as main IL-10 producers. 
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FIGURE 25: Stimulation of (A) peritoneal excudate cells (PEC) and (B) splenocytes derived from naïve or 
cystatin-treated animals with Av17. Shown are mean values of IL-10 levels after 24h stimulation of 5 animals 
per group. naïve: PBS-treated mice; Av17ip/OVAin: i.p. injections of Av17 and i.n. challenge with ovalbumin 
(OVA); Av17ip/Av17in: intraperitoneal and intranasal Av17 application; 
To examine IL-10 release in Av17-stimulated Av17-PECs in more detail, the cells were 
adhered overnight on cell culture plate surfaces and thus enriched for macrophages (by 
discarding supernatants). When these enriched PEC macrophages were stimulated with Av17 
or a mutated form of cystatin (mAv17, no proteinase inhibitor function) a clearly increased 
secretion of IL-10 was found. In comparison, incubation with medium or the control proteins 
DHFR (dihydrofolat-reductase) and Cysele2 (C. elegans cystatin 2, a cystatin homolog of a 
non-parasitic helminth) did not induce IL-10 secretion. Furthermore IL-10- secretion in 
response to Av17 stimulation could not be blocked by polymyxin B (10μg/ml). Interestingly, 
lipopolysaccharide (LPS) stimulation also induced IL-10-secretion but this effect could be 
clearly inhibited by addition of polymyxin B (Fig. 26).  
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FIGURE 26: Stimulation of enriched PEC derived from cystatin treated animals. Shown is the IL-10 release in 
response to 24h stimulation with filarial cystatin (Av17), mutated Av17 (mAv17), unrelated control protein 
(DHFR), lipopolysaccharid (LPS), medium (RPMI) and C.elegans cystatin 2 (Cysele2). 
These data indicate, that only parasite-derived cystatin leads to IL-10 production, as verified 
by a lack of IL-10 production with soil-nematode derived cystatin (Cysele2). Furthermore the 
data suggest that IL-10 production is not due to LPS contamination, as addition of the LPS-
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ligand polymyxin B could only block LPS-induced IL-10 production but not Av17-induced 
secretion.  
3.2. Av17 in allergic skin-disease: ovalbumin-induced atopic dermatitis 
Considering the protective effect of cystatin application in the model of allergic airway 
inflammation led to the question whether effects of cystatin application would be restricted to 
the Th2 dependent asthma model or if Av17 would also yield amelioration of disease on 
another allergy model, namely atopic dermatitis. The dermatitis model is described to consist 
of a mixed Th2 and Th1 reaction and inflames a different tissue (cutaneous vs mucosal). This 
approach aimed to provide insight into the “effector range” of cystatin. Furthermore, 
dermatitis is often claimed to be the start of the atopic march, meaning that a high percentage 
of dermatitis patients develop asthma, food allergy or other allergic diseases in their later life 
(Boguniewicz 2004). Inhibiting dermatitis could therefore raise a possibility to stop the atopic 
march. 
3.2.1. Treatment with filarial cystatin prevents eczema in murine atopic dermatitis 
To induce atopic dermatitis BALB/c mice were injected intraperitoneally (i.p.) with the model 
allergen ovalbumin (OVA) and subsequently challenged epicutaneously (e.c.) via OVA-
saturated patches. Treatment with purified recombinant cystatin from A. viteae was performed 
during sensitization with OVA and along with the epicutaneous challenge with the allergen 
(Fig. 25). 
Atopic dermatitis (A.D.) 
OVA 
Av17 
i.p.                                 i.p.     i.p.  
1 14  7 22   25   day 42   45   63  66   
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FIGURE 27: Model of murine atopic dermatitis. OVA i.p. indicates sensitization with ovalbumin; OVA e.c. 
symbols epicutanous treatment with ovalbumin, 2 cycles of 3 days; Av17 i.p. signals intraperitoneal injection of 
filarial cystatin (Av17). 
Treatment with 6 doses of cystatin (20 μg each) but not with the irrelevant recombinant 
control protein murine dihydrofolate reductase (DHFR) lead to significantly reduced 
occurrence and severity of eczema. This was evaluated by assessment of a clinical skin score 
depending on comparison of erythema, edema/papulation, excoriation/crusting, dryness and 
extension of skin and eczema, respectively. Clinical skin score in sensitized animals that were 
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treated along with cystatin (OVA/Av17-group) showed a mean skin score of 4.2, whereas 
both control groups had elevated skin scores of 7.4 (OVA, p< 0.04) or 10.8 (DHFR, p<0.008) 
respectively compared to a skin score of 3.0 in naïve mice (Fig. 28). 
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FIGURE 28: Assessment of clinical skin score values in the dermatitis model. Shown are mean values for 
groups and representative photos of patch areas on the belly (indicated by black circles). naive: i.p. and e.c. PBS-
treated mice; OVA: i.p. and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected 
with filarial cystatin; OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. 
Representative data of 2 individual experiments with 3-6 animals per group. *p < 0.05, **p < 0.005. 
These findings were underlined by the measurement of thickness of epidermis in 
eczema/patch regions. Treatment with cystatin led to a decrease in epidermis thickness back 
to naïve levels (32 μm and 30 μm) in comparison to values of 52 μm and 60 μm in OVA and 
OVA/DHFR group (p < 0.001), respectively (Fig. 29). 
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FIGURE 29: Thickness of epidermis was measured in skin sections of patch areas. Shown are mean values for 
groups and representative pictures of sections stained with he. naive: i.p. and e.c. PBS-treated mice; OVA: i.p. 
and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected with filarial cystatin; 
OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. Measurement was performed 
by A. Dahten. Representative data of 2 individual experiments with 3-6 animals per group. *p < 0.05. 
Both the clinical skin score and measurement of epidermis thickness clearly revealed that 
cystatin application does lead to prevention or amelioration of eczema formation, an effect not 
seen for the control protein. 
3.2.2. Cell infiltration into challenged skin is altered by cystatin treatment 
In order to obtain information on cell influx into treated tissue, sections of patched skin 
regions were histologically analysed. Staining for CD4 and CD8 T cells as well as for mast 
cell and CD11c positive dendritic cell infiltration was performed. Treatment with the 
immunomodulator led to significantly less infiltration of CD4 helper T cells (p < 0.02) and a 
clear trend of less mast cells compared to controls (Fig. 30A, B).  
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FIGURE 30: Histological skin sections reflecting cell influx. (A) CD4 positive T cells and (B) mast cells were 
stained in individual sections. Shown are mean values for groups. naive: i.p. and e.c. PBS-treated mice; OVA: 
i.p. and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected with filarial cystatin; 
OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. Staining was performed by A. 
Dahten. Representative data of 2 individual experiments with 3-6 animals per group. *p < 0.05. 
Interestingly, in these experiments influx of both CD8 positive T cells and CD11c positive 
dendritic cells was not linked to severity of eczema (data not shown) as both cell types were 
found also in low levels in DHFR-treated animals, but skin score was dramatically increased 
in DHFR-groups. 
3.2.3. Changes in OVA-specific IgE in sera upon cystatin-treatment 
To analyze effects of cystatin treatment on sensitization, allergen specific antibodies were 
measured according to the analysis in the asthma model. Sera of sensitized and challenged 
animals treated along with cystatin contained significantly reduced allergen-specific IgE 
levels (p < 0.01) however also the control protein treated group revealed a trend to reduction 
though this did not reach statistical significance (Fig. 31A). 
FIGURE 31: Allergen-specific IgE-levels in filarial cystatin-treated animals. Shown are (A) mean values of 
ovalbumin-specific IgE in LU (lab units) and (B) degranulation of rat basophil cells (RBL) in response to OVA-
antigen and sera, indicated by percentage of mediator release. naive: i.p. and e.c. PBS-treated mice; OVA: i.p. 
and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected with filarial cystatin; 
OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. Representative data of 2 
individual experiments with 3-6 animals per group. *p < 0.05. 
OVA-IgG1- and OVA-IgG2a- amounts were found to be unaltered by cystatin treatment, 
though they showed a trend towards down-modulation in comparison to the OVA-group (not 
shown). Total IgE-concentrations also tended to be decreased but without reaching statistical 
significance (not shown). In addition, a mediator release test to investigate IgE-activity was 
performed and resulted in equal activity-levels for all OVA-sensitized and challenged groups 
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not dependent on protein treatment (Fig. 31B). This indicates that there is a downmodulatory 
effect of cystatin on allergen-specific IgE in the dermatitis model but that reduction of OVA-
IgE levels is not the crucial factor for amelioration in this approach. 
Therefore, it can be concluded that cystatin treatment decreases the clinical picture of atopic 
dermatitis and leads to alterations in cell recruitment but this is obviously not dependent on 
antibody levels in this late phase of the model. This fits to reports that the late chronic phase 
of dermatitis is Th1-dependent, in contrast to the early acute phase described to be Th2-
dependent (Leung 2004). 
3.2.4. Cytokine pattern in spleen indicates altered response to the allergen 
Systemic cytokine production was analyzed in splenocyte cultures by stimulation of spleen 
cells with the allergen ovalbumin (OVA). Splenocytes derived from cystatin-treated animals 
secreted clearly reduced amounts of OVA-specific IL-4, IL-5 and IL-10 although this did not 
reach statistical significance. However, all three cytokines were found to be up-regulated in 
control groups (Fig. 32A, B, C). IFN- and TNF- were found to be not induced or the latter 
even undetectable (data not shown). Stimulation of splenocytes with filarial cystatin revealed 
upregulated IL-10 secretion in splenocytes derived from cystatin-treated mice as observed in 
the asthma model (data not shown). This indicates that cystatin-treatment did clearly alter 
systemic response to the allergen. 
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FIGURE 32: Splenocytes of mice in the dermatitis model were stimulated with ovalbumin (OVA) and release 
of OVA-specific (A) IL-4, (B) IL-5 and (C) IL-10 was measured. naive: i.p. and e.c. PBS-treated mice; OVA: 
i.p. and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected with filarial cystatin; 
OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. Representative data of 2 
individual experiments with 3-6 animals per group. 
3.2.5. Local cytokine production in skin is altered by cystatin treatment 
To monitor cytokines directly at the site of inflammation skin samples of the patch region 
were analyzed via real time PCR. Levels of IL-4-, IL-10- and IFN-- mRNA in OVA/Av17 
patch region skin compared to OVA- group were decreased (Tab. 2). IL-4 and IL-10 
transcripts were elevated in OVA/DHFR group whereas IFN--mRNA was still decreased. 
However none of these changes reched statistical significance. Interestingly, an elevation of 
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anti-inflammatory and wound-healing-associated TGF--mRNA levels in cystatin co-treated 
tissue samples compared to OVA- group was detected (p < 0.031) and this increase was about 
50% lower in the control-protein co-treated group. Foxp3 levels in skin of Av17-treated 
animals were not altered (data not shown). 
 Fold  (mean)  change
OVA OVA/Av17 OVA/DHFR Compared to OVA 
IL-4 1,04 +/- 0,17 0,33 +/- 0,13 4,22 +/- 1,85 
IL-10 1,11 +/- 0,26 0,91 +/- 0,21 4,09 +/- 1,70 
TGF-ß 2,06 +/- 1,60 17,8 +/- 7,40 7,89 +/- 4,60 
IFN- 1 +/- 0 0,59 +/- 0,29 0,22 +/- 0,06 
Table 2: Skin patch regions were analysed in real time PCR for mRNA of cytokines. Shown are fold changes in 
local cytokines compared to OVA-group indicated by mean values +/- SEM. Green: down-regulation of mRNA; 
Red: up-regulation of mRNA; OVA: i.p. and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated 
mice injected with filarial cystatin; OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein 
DHFR. 
3.2.6. Cystatin restores Treg numbers in mesenteric lymph nodes but does not alter 
          inguinal lymph nodes 
As there are implications that Treg cells may play a role in atopic dermatitis the skin-draining 
lymph node cells (inguinal lymph node cells, ILN) and unrelated mesenteric lymph node cells 
(MLN) were analyzed for the expression of the surface markers CD4, CD25 and CD103. 
Approximately 94 - 98% of the so-defined Treg cells expressed Foxp3 (data not shown).  
The flow cytometry pointed out, that the proportion of Treg cells was significantly reduced in 
OVA (4.2 %) - and OVA/DHFR (4.5 %) - controls compared to naïve MLNCs (5.4 %) (p < 
0.02). Mesenteric lymphocytes of OVA/Av17-treated animals showed a slight increase (6.3%) 
as compared to the naïve group but this ascent was not significant. However, Treg cells in 
control versus Av17-treated animals demonstrated a significant alteration. (p < 0.007, Av17 to 
OVA; p < 0.04, Av17 to DHFR; Fig. 33A). 
percentage  CD25+/CD103+ in CD4+
0
2
4
6
8
MLN
%
 p
os
iti
ve
 c
el
ls naive
OVA 
OVA/Av17
OVA/DHFR
** **
percentage CD103+/CD25+ in CD4+ 
0
2
4
6
8
10
ILN
%
 p
os
iti
ve
 c
el
ls
A B 
FIGURE 33: Percentages of CD4/CD25/CD103 positive cells in (A) mesenteric lymph nodes (MLN) and (B) 
inguinal lymph nodes (ILN). Shown are mean values of groups. naive: i.p. and e.c. PBS-treated mice; OVA: i.p. 
and e.c. ovalbumin-treated mice; OVA/Av17: i.p. and e.c. OVA-treated mice injected with filarial cystatin; 
OVA/DHFR: i.p. and e.c. OVA-treated mice injected with control protein DHFR. Representative data of two 
experiments with 3-6 animals. *p < 0.05, **p < 0.005. 
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Analysis of inguinal lymph nodes revealed unaltered proportions of Treg cells for all tested 
groups (about 6.5 %, Fig. 33B), pointing toward only minor or no involvement of Treg cells 
in cystatin effects on dermatitis as Tregs in mesenteric lymph nodes should not be directly 
involved in amelioration of skin lesions. 
3.3. Heligmosomoides polygyrus infection and allergy 
3.3.1. Infection with the gastrointestinal nematode H. polygyrus ameliorates allergic 
          airway inflammation but not the development of atopic dermatitis 
Many reports on worm infections and allergy describe a strong negative correlation, resulting 
in less allergies in worm-infected individuals (see introduction). However some studies also 
point out positive correlations and enhancement of allergies by parasites. Apart from “the 
state” of infection (chronicity vs acute, as well as adult worm numbers) and the genus of the 
parasite (Smits 2007, Boitelle 2005) there also seem to be differences depending on the 
quality of the allergic disease and the biology or location of the parasite. To clarify the role of 
a gastrointestinal nematode infection (H. polygyrus) on allergen mediated sensitization and 
allergic disease two murine models were studied: ovalbumin (OVA)-induced airway disease, 
associated with the mucosal compartment and OVA-induced skin inflammation, linked to 
cutaneous tissue. 
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FIGURE 34: Model of worm infection in (A) allergic airway inflammation and (B) atopic dermatitis. Mice were 
sensitized intraperitoneally with the allergen ovalbumin (OVA i.p.) and challenged intranasally (i.n.) in the 
asthma model and epicutaneously (e.c.) in the dermatitis model. Infection with the gastrointestinal nematode on 
day 1 with infective larval stage 3 (H.poly L3). 
In both approaches, BALB/c mice were infected orally with 150 L3 of H. polygyrus on the 
first day of intraperitoneal sensitization with the model allergen ovalbumin (OVA). 
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Subsequently, mice were challenged with OVA via the airways (i.n.) (Fig. 34A) or via OVA-
saturated skin patches (e.c.) (Fig. 34B). 
In the asthma model both the OVA-group and H. polygyrus-infected mice that were sensitized 
and challenged with OVA (OVA/Hp-group), showed significantly increased total cell 
numbers in BALF (p < 0.009, p < 0.01) in comparison to naïve control mice (Fig. 35A). 
However, clear differences in the type of recruited cells were found between the OVA-group 
and the OVA/Hp-group. In the OVA-group the increase in total cells was due to a significant 
increase of eosinophils (p < 0.009). In contrast, in OVA/Hp-animals eosinophils in the BALF 
were significantly decreased (p < 0.03) but a trend towards an increase in macrophage 
recruitment into the lung (p < 0.06; Fig. 35A) was observed. Helminth-infected control 
groups, which were neither sensitized nor challenged with allergen, showed no increase of 
BAL cell numbers (data not shown). 
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FIGURE 35: Infection with the gastrointestinal nematode Heligmosomoides polygyrus alters (A) eosinophil and 
macrophage numbers in BALF and (B) airway hyperreactivity of infected animals in response to increasing 
metacholin (MCh) concentrations in the asthma model. Shown are mean values of cell numbers and Penh (pause 
enhanced) values. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-treated animals; OVA/Hp: OVA-treated 
and H.polygyrus infected mice. Representative data of 2 individual experiments with 5-6 animals per group *p < 
0.05; **p < 0.005. 
Measurement of airway hyperreactivity (AHR) in response to metacholin (MCh) stimulation 
of OVA/Hp-mice revealed a trend towards a down-regulation, although these changes did not 
reach statistical significance in comparison to the OVA-group (Fig. 35B).  
These data show that the infection with H. polygyrus has a positive influence on airway 
inflammation, clearly reflected by eosinophil numbers, and thereby interferes with the 
development of airway disease. 
These findings were in contrast to the influence of the intestinal worm infection on the non-
mucosal allergic reaction, the murine model of OVA-induced atopic dermatitis.  
After induction of eczema by systemic (i.p.) sensitization with ovalbumin and subsequent 
epicutaneous (e.c.) challenge with the allergen the clinical skin score was assessed. 
Interestingly, a concomitant infection with H. polygyrus did not improve clinical skin score of 
eczematous mice (Fig. 36A) but rather aggravated lesions (mean skin scores 7.4 in OVA-
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group, 8.4 in OVA/Hp-group, p < 0.02). These findings were in accordance with an increase 
in the thickness of epidermis observed in histological sections of the eczema region. 
Thickness of epidermis was not significantly different between the OVA- and the OVA/Hp-
group (52μm and 61μm; p < 0.001; Fig. 36B) but again a trend towards an aggravation by the 
nematode infection was detected.  
A B 
FIGURE 36: Infection with H. polygrus in the dermatitis model aggravates (A) clinical skin score and (B) 
increase of thickness of epidermis. In the top panel mean values of groups are shown, the base panel consists of 
representative pictures of eczema (patch region indicated by a black circle) and epidermis sections. 
Measurements were performed by A. Dahten. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-treated 
animals; OVA/Hp: OVA-treated and H. polygyrus infected mice. Representative data of 2 individual 
experiments with 5-6 animals per group. *p < 0.05; **p < 0.005.  
These data indicate that H. polygyrus infection rather increased than ameliorated atopic 
dermatitis which stands in contrast to the ameliorative effect in the asthma model. 
3.3.2. Allergen-specific humoral immune response of worm-infected mice in the asthma 
          and dermatitis model is altered 
Analyzing allergen-specific and total IgE in sera of mice in the asthma model clearly showed 
decreased levels of allergen-specific IgE (p < 0.002) in OVA/Hp-mice. In contrast, total IgE 
levels were significantly increased (p < 0.002) in the OVA/Hp group (Fig. 37A, B). 
Furthermore, allergen-specific IgG1 (p < 0.02) in sera of OVA/Hp-treated mice was 
significantly decreased (Fig. 37C). Allergen-specific IgG2a levels remained unaltered in the 
helminth-infected mice (data not shown).  
Analysis of IgE in sera of A.D.-mice showed that concomitant infection with H. polygyrus 
significantly reduced allergen-specific IgE (p < 0.01, Fig. 37D), whereas total IgE was 
significantly elevated as compared to the OVA-group (Fig. 37E). Furthermore OVA-specific 
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IgG1 was clearly down-modulated by worm infection (Fig. 37F), reflecting the observations 
of the asthma model. 
Allergen-specific IgE was additionally determined by a basophil release assay (RBL-assay). 
No changes in mediator release were detected when comparing the OVA-group with the 
OVA/Hp-group in both models (not shown).  
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FIGURE 37: Antibody levels in sera of animals in the asthma model (upper panel) and the atopic dermatitis 
(A.D.) model (lower panel). Shown are mean values of (A, D) ovalbumin (OVA)-specific IgE, (B, E) total IgE 
and (C, F) OVA-specific IgG1. LU indicates lab units. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-
treated animals; OVA/Hp: OVA-treated and H. polygyrus infected mice. Representative data of 2 individual 
experiments with 5-6 animals per group. *p < 0.05; **p < 0.005. 
These data indicate that in both allergy models a concomitant infection with the 
gastrointestinal nematode led to significantly diminished allergen-specific antibody 
concentrations in sera whereas total IgE levels remained elevated. 
3.3.3. Local and systemic cytokine analysis in asthma and dermatitis differ 
To determine the mechanism by which the nematode-infection induced amelioration of the 
allergic airway inflammation in comparison to pathological skin responses in the A.D.-model 
systemic and local cytokine production was analyzed. Stimulation of splenocytes with the 
allergen OVA led to reduced levels of IL-4 (p < 0.06, Fig. 38A) and IL-10 (p < 0.002, Fig. 
38C) in the OVA/Hp-group in comparison to the OVA-group in the asthma model. No 
differences were found with regard to IL-5 production (Fig. 38B). In contrast, stimulation of 
spleen cells of OVA/Hp animals with parasite antigen led to secretion of high amounts of  
IL-4, IL-5 (p < 0.008) and IL-10 (p < 0.002) (Fig. 38G, H, I), which could not be observed in 
uninfected animals.  
43 
Results 
A.D. 
asthma 
A.D. 
asthma 
0
250
500
750
1000
pg
/m
l **
0
100
200
300
400
500
pg
/m
l **
0
50
100
150
200
250
pg
/m
l **
0
50
100
150
200
pg
/m
l **
0
500
1000
1500
2000
pg
/m
l
**
0
1000
2000
3000
pg
/m
l
**
Hp-specific IL-4 Hp-specific IL-5 Hp-specific IL-10 
Hp-specific IL-4 Hp-specific IL-5 Hp-specific IL-10 
0
50
100
150
200
250
pg
/m
l
0
1000
2000
3000
pg
/m
l
0
1000
2000
3000
4000
pg
/m
l
**
0
50
100
150
200
250
pg
/m
l
0
500
1000
pg
/m
l
0
500
1000
1500
2000
2500
pg
/m
l
OVA-specific IL-4 OVA-specific IL-5 OVA-specific IL-10 
OVA-specific IL-4 OVA-specific IL-5 OVA-specific IL-10 
D E F 
G H I
J K L 
naive OVA OVA/Hp 
A B C 
FIGURE 38: Cytokine production of splenocytes in the asthma and the dermatitis (A.D.) model. Ovalbumin 
(OVA)-specific production of (A) IL-4, (B) IL-5 and (C) IL-10 in the airway inflammation model. OVA-specific 
secretion of the cytokines (D) IL-4, (E) IL-5 and (F) IL-10 in the dermatitis model. Cytokine secretion upon 
stimulation of splenocytes with H.polygyrus antigen (Hp) in the asthma model: (G) IL-4, (H) IL-5 and (I) IL-10. 
Hp-specific cytokine production the in dermatitis model: (J) IL-4, (K) IL-5, (L) IL-10. naïve: PBS-treated 
animals; OVA: ovalbumin (OVA)-treated animals; OVA/Hp: OVA-treated and H. polygyrus infected mice. 
Representative data of 2 individual experiments with 5-6 animals per group. *p < 0.05; **p < 0.005. 
In comparison, allergen-specific cytokine production in spleen culture supernatants of A.D.-
animals showed no significant differences between the OVA- and OVA/Hp-mice regarding 
the cytokines IL-4, IL-5, IL-10 (Fig. 38D, E, F). However, stimulation of spleen cultures with 
parasite antigen resulted in up-regulation of IL-4 (p < 0.0019), IL-5 (p < 0.004) and IL-10  
(p < 0.0098) (Fig. 38J, K, L) in the OVA/Hp group, as observed in the asthma model. 
Interestingly, Hp-specific IL-10 production in the A.D.-model was profoundly lower 
compared to worm-infected animals in the asthma model. 
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To investigate cytokines at the site of inflammation BAL fluid was analysed for production of 
IL-4, IL-5, IL-10 and TGF-. Only TGF- measurement in BAL fluid exhibited differences 
between the OVA-group and the OVA/Hp-group, although the decrease of TGF-ß production 
in the OVA/Hp group was not statistical significant (Fig. 39). 
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FIGURE 39: Measurement of transforming growth factor-ß (TGF-
ß) in bronchoalveolar lavage fluid (BALF) of mice in the asthma 
model. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-
treated animals; OVA/Hp: OVA-treated and H. polygyrus infected 
mice. Representative data of 2 individual experiments with 5-6 
animals per group. 
In the dermatitis model cytokine mRNA was measured in the inflamed skin via real time 
PCR. The analyses indicated a trend towards up-regulated IL-4- and IL-10- mRNA levels 
though this did not reach statistical significance. However, TGF- mRNA amounts in the 
OVA-Hp-group were significantly reduced compared to naïve animals (p < 0.042) (Tab. 3). 
 fold change (mean)   
OVA naive OVA/Hp compared to OVA 
IL-4 2.14 +/- 0.76 1.0 +/- 0.15 0.5 +/- 0.01 
IL-10 1.1 +/- 0.22 0.56 +/- 0.19 2.10 +/- 0.70 
TGF-ß 1.7 +/- 1.00 4.3 +/- 2.30 0.42 +/- 0.13 
TABLE 3: Skin patch regions were analysed in real time PCR for mRNA of cytokines. Shown are fold changes 
in local cytokines compared to OVA-group indicated by mean values +/- SEM. Green: down-regulation of 
mRNA levels; Red: up-regulation of mRNA levels; OVA: i.p. and e.c. ovalbumin-treated mice; naïve: i.p. and 
e.c. PBS-treated mice; OVA/Hp: i.p. and e.c. OVA-treated mice infected with H. polygyrus. 
Hence, the nematode infection exhibited a different impact on the cytokine production within 
the two allergy models. So far, it seems that lower amounts of Hp-specific IL-10 or lack of 
TGF-ß in lesions could be the reason for the detrimental effect of H. polygyrus in A.D.  
3.3.4. Cellular infiltration in atopic skin is partly altered by H.polygyrus infection 
Although the clinical outcome was aggravated and the thickness of epidermis was elevated in 
OVA/Hp A.D.-mice, differences in the numbers of cells infiltrating the skin lesions were 
observed. Skin sections stained for CD4+ T cells showed significantly increased infiltration of 
T helper cells in OVA-mice mice suffering from dermatitis in comparison to naïve mice  
(p < 0.001). In contrast, numbers of infiltrating T cells were significantly decreased in 
OVA/Hp- mice (p < 0.001, Fig. 40A). However, infiltration of mast cells was found to be 
significantly enhanced in OVA/Hp-mice in inflamed skin areas (p<0.007 compared to OVA, 
Fig. 40B).  
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FIGURE 40: Cells infiltration in patched skin regions in the dermatitis model. (A) T helper cells (CD4) and (B) 
mast cells were stained in skin sections. Shown are mean values of cell numbers counted in high power fields 
(HPF) in a 200 fold magnification. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-treated animals; 
OVA/Hp: OVA-treated and H. polygyrus infected mice. Staining was performed by A. Dahten. Representative 
data of 2 individual experiments with 5-6 animals per group. **p < 0.005. 
These data indicate, that H. polygyrus infection has no positive influence on the clinical 
outcome of atopic dermatitis, albeit it induces significant changes in cell recruitment into the 
inflamed skin. Although not described in this dermatitis model so far, it is tempting to 
speculate that the increase of mast cells found in skin of worm infected mice might account 
for aggravation of inflammation, mediated via a different mechanism. 
3.3.5. H. polygyrus infection leads to induction of regulatory T cells in mesenteric and 
peribronchial but not in inguinal lymph nodes 
To gather information whether regulatory T cells are involved in the influence of H. polygyrus 
on these two atopic immune responses Treg cells, characterized by the expression of the 
surface markers CD4+CD25+CD103+, in the corresponding lymph nodes were analyzed. In 
the asthma model analysis of peribronchial lymph node cells (PBLNC) of OVA/Hp-mice 
showed a significant increase in Treg cells (p < 0.05) compared to the OVA-group (Fig. 41A, 
B). More than 95 % of the Treg cells were determined to be Foxp3 positive (data not shown). 
Such an increase in Treg cells was not found in PBLN cells of H. polygyrus-infected mice that 
were not sensitized and challenged with the allergen (data not shown). A significant increase 
of Treg cells could also be found in the mesenteric lymph node cells in the OVA/Hp group of 
the asthma model (p < 0.05; Fig. 41A, C). 
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FIGURE 41: Analyses of T regulatory cells characterized by the expression of the surface markers CD4, CD25, 
CD103. (A) Representative dot plots of peribronchial lymph node cells (PBLN) and mesenteric lymph node cells 
(MLN) in animals of the asthma model. (B) Mean values of Treg numbers in PBLN of groups. (C) Mean values 
of Treg numbers in MLN in groups. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-treated animals; 
OVA/Hp: OVA-treated and H. polygyrus infected mice. Representative data of 2 individual experiments with 5-
6 animals per group. *p < 0.05. 
Regarding the numbers of CD4+CD25+CD103+ regulatory T cells in the OVA/Hp-group of 
the A.D. model, a significant increase of Treg numbers in mesenteric lymph node cells was 
determined (p < 0.05; 4 % to 7 %; Fig. 42A, C). However, this significant increase in MLNC 
was in contrast to the situation found in the skin-draining inguinal lymph node cells. There, no 
altered Treg numbers were observed in the OVA/Hp-group (6.2 % to 6.8 %; Fig. 42A, B).   
FIGURE 42: Analyses of T regulatory cells characterized by the expression of the surface markers CD4, CD25, 
CD103. (A) Representative dot plots of inguinal lymph nodes (ILN) and mesenteric lymph nodes (MLN) in 
animals of the dermatitis (A.D.) model. (B) Mean values of Treg numbers in ILN of groups. (C) Mean values of 
Treg numbers in MLN of groups. naïve: PBS-treated animals; OVA: ovalbumin (OVA)-treated animals; 
OVA/Hp: OVA-treated and H.polygyrus infected mice. Representative data of 2 individual experiments with 5-6 
animals per group. *p < 0.05. 
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Furthermore, Foxp3 in skin lesions was measured by real time PCR. In skin lesions of the 
OVA/Hp-group no Foxp3 signal could be determined. Strikingly, also in atopic animals 
without worm infection Foxp3 in skin lesions was dramatically decreased (Tab. 4).  
 fold change   
OVA naive OVA/Hp compared to OVA 
Foxp3 1.003 +/- 0.2 10.00 +/- 5.2 not detectable 
TABLE 4: Skin patch regions were analysed via real time PCR for mRNA levels of the regulatory T cell marker 
Foxp3. Shown is the fold change of mRNA amounts compared to the OVA-group indicated by mean values +/- 
SEM. OVA: i.p. and e.c. ovalbumin-treated mice; naïve: i.p. and e.c. PBS-treated mice; OVA/Hp: i.p. and e.c. 
OVA-treated mice infected with H. polygyrus. 
These data point in the direction that H. polygyrus infection leads to protection in airway 
inflammation because of an elevation in Treg numbers in the draining peribronchial lymph 
nodes (PBLN). Regarding atopic dermatitis, the data suggest that the gastrointestinal 
nematode is not able to enhance Treg numbers in the draining inguinal lymph nodes (ILN) or 
in patched skin regions, thereby having no ameliorative effect on this cutaneous model.  
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4. Discussion 
4.1. Av17 and Allergic Airway Hyperreactivity (AHR) 
4.1.1. Cystatin treatment modulates the allergic Th2 response 
Infections with parasitic worms bear the potential to suppress allergic and inflammatory 
immune responses. Negative correlations between helminth infection and allergic disease 
have been observed in human field studies and especially in animal models (Maizels 2004, 
Fallon 2007). This work aimed to study if such protective effects could be exerted by single 
immunomodulatory proteins and provides evidence that the cysteine proteinase inhibitor of 
the parasitic nematode Acanthocheilonema viteae (Av17, cystatin) can indeed suppress 
allergic inflammation. 
The in vivo experiments with recombinant filarial cystatin, expressed in E. coli, clearly show 
that application of this helminth immunomodulator in a murine model of ovalbumin-induced 
airway inflammation and hyperreactivity, during or even after allergen sensitization, 
counteracted the Th2 effector mechanisms responsible for allergic airway disease. The 
downmodulation of the Th2 response was accomplished in several ways.  
First, cystatin treatment significantly reduced the recruitment of inflammatory cells, 
particularly eosinophils, into the lungs. Blood and tissue eosinophilia are hallmark signs of 
helminth infection, allergy and asthma (Prussin 2006). The release of effector molecules by 
these cells leads to tissue damage (Trivedi 2007, Rothenberg 2006). This mechanism was 
effectively prevented by interference with eosinophil recruitment by cystatin treatment.  
Second, after application of cystatin the production of allergen-specific and total IgE was 
strongly downmodulated. This resulted in less efficient sensitization of mast cells and 
basophils (Bradding 2006), as determined by decreased degranulation of basophils sensitized 
with sera of cystatin/OVA-treated mice. Histamine, released by mast cells, has important 
immunomodulatory functions, as application of Histamine-1-receptor (H1R)-antagonists prior 
or during sensitization prevents allergen induced airway inflammation and AHR by altering 
the expression of costimulatory molecules on APCs (Blümchen 2004).  
Another mechanism influencing mediator release might be coaggregation of FcRI and 
FcRIIB that activates an ITIM (immunoreceptor tyrosine-based inhibition motif) that 
prevents activation of mast cells (Kraft 2006). For this coaggregation cystatin would have to 
act as a dimer or even polymer in vivo. These structures were observed in preparations of 
chicken and human cystatin (He 2005; Janowski 2001), and have also been found for Av17 
(T. Buhrke, personal communication). 
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Third, cystatin treatment reduced local production of the Th2 cytokine IL-4 in BALF as well 
as systemic IL-4 production by spleen cells. IL-4 plays a major role in the development of 
allergic reactions: It is crucial in the induction of the production of IgE by mediating class-
switch (Poulsen 2007). Furthermore IL-4 promotes Th2 responses by stimulating Th2 cells 
and directing naïve T helper cells into Th2 direction (indirect effect via dendritic cells, 
Spellberg 2001). Interleukin-4 is also described to enhance tissue homing of inflammatory 
effector cells (Romagnani 2004). Therefore, it is assumed that the reduction of IL-4 levels by 
cystatin treatment contributed to the inhibition of IgE production and the lowering of Th2 
responses in this model.  
Absence of high IL-4 levels could also provide the possibility to switch the immune response 
from “atopic” Th2 to “non-atopic” Th1. This aspect has been proven to be important in the 
context of bacterial immunomodulators, as TLR2 and TLR4 agonists (Velasco 2005, Gerhold 
2006). These components act through stimulation of Th1 responses, as evidenced by elevated 
production of IFN- and other Th1 cytokines, thereby blocking Th2 response. Th1 and Th2 
cells cross-regulate each other by expression of IFN- to stop IL-4 secretion and 
differentiation of Th0 cells to Th2 cells or by IL-4 and IL-10 secretion that blocks IL-12 and 
IFN- production and therefore differentiation to Th1 respectively (Gajewski 1988, Ohmori 
1997, Ito 1999). 
However, filarial cystatin stands in contrast to typical TLR ligands: There was never 
production of the cytokines IFN- or IL-12 observed in cystatin-treated animals, arguing for a 
different mechanism. Furthermore filarial cystatin was shown to be able to inhibit Th2-related 
as well as macrophage-related inflammation (colitis, Schnoeller 2008) and, as presented in 
this work, also mixed Th1/Th2 responses (dermatitis), which is clearly not possible by the 
Th1/Th2 shift described for TLR2 and TLR4 agonists. Regarding possible contaminations of 
the protein preparation, it has to be said, that the classical TLR4 ligand LPS was described to 
ameliorate airway eosinophilia and OVA-IgE only in high concentrations (about 10 μg per 
mouse) and had no effect on AHR development (Gerhold 2002). Low dose administration of 
LPS (<10 ng; i.p.) was shown to even enhance airway eosinophilia (Delayre-Orthez 2004). 
The low dose applications described in literature still comprise more endotoxin than leftover 
LPS found in cystatin preparations (max. 40 pg per application). Also positive effects of BCG 
(Bacillus Calmette Guerin, Mycobacterium bovis) are thought to be mediated by a switch 
towards Th1 response, involvement of TLR receptors and strong IL-12 production (Barlan 
2006). However IL-12 was also not induced by cystatin treatment. 
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4.1.2. Role of the anti-inflammatory cytokines IL-10 and TGF-ß 
Filarial cystatin has been described in recent publications as a potent immunomodulator in 
vitro. In these studies Av17 (Hartmann 1997) and its human counterpart Ov17 (Onchocerca 
volvolus cystatin) (Schoenemeyer 2001) could be shown to induce IL-10 secretion in 
splenocytes or PMBC respectively. After depletion of monocytes, IL-10 secretion was 
abrogated, pointing to macrophages as the main producing cells. In addition parasitic cystatin 
was proven to inhibit proteinases (human cathepsins L and S) and several costimulatory 
molecules (CD86, HLA-DR) involved in antigen-processing and presentation. Further studies 
pointed out, that these effects were characteristic of parasite-derived cystatins as cystatin of 
the soil-nematode C. elegans (Cysele 2) did not lead to IL-10 induction and inhibited different 
cathepsins (Schierack 2003). Finally Av17 could be shown to be a potent suppressor of T cell 
proliferation probably mediated via IL-10. 
Keeping this in mind brings the anti-inflammatory cytokine IL-10 in the spot light. To 
corroborate this hypothesis, in this work, application of anti-IL-10-receptor (IL10R) 
antibodies to block the mediator was performed. Blocking of IL-10 receptor completely 
reversed the effect of cystatin on cell recruitment, production of IgE and airway 
hyperreactivity.  
Tournoy and co-workers described that IL-10 therapy in mice successfully inhibited airway 
inflammation and nonspecific airway responsiveness (Tournoy 2000). Furthermore IL-10 
gene delivery in mice suppresses airway hyperreactivity (AHR) by down-modulation of APC 
functions (Nakagome 2005). Taken together with reports suggesting that production of IL-10 
by Treg cells plays a central role in control of allergic airway disease (Hawrylowicz 2005b) 
and that systemic production of IL-10 is capable to inhibit the development of airway hyper-
responsiveness and allergic inflammation (Fu 2006, Urry 2006), it seems fitting to speculate 
that IL-10 is a key element in the cystatin-induced immunomodulation in asthma. Even more 
intriguing, the depletion of macrophages led to an abrogation of IL-10 production and 
aggravation of inflammation, whereas Treg depletion did not influence the systemic release of 
IL-10 and did not block the protective cystatin effect to the same extend. 
IL-10 was reported to modulate Th2 responses by a broad range of suppressive mechanisms: 
By suppression of allergen-specific IgE production and concomitant induction of non-
inflammatory antibody isotypes, by reduction of pro-inflammatory cytokines released by mast 
cells, basophils and eosinophils, and by indirect interference with Th2-associated phenomena 
such as mucus production (Taylor A 2006, Larche 2006). Thus, IL-10 seems indeed to be 
capable of redirecting pathologic allergic responses. There is also evidence for positive effects 
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of IL-10 from human studies: in allergic patients undergoing successful immunotherapy IL-10 
levels are increased (Akdis 2006, Bohle 2007). IL-10 has also been shown to inhibit IgE 
induced mast cell activation in humans (Royer 2001). 
In addition to its effects on Th2 responses IL-10 is also known to modulate the maturation of 
dendritic cells and inhibit the expression of MHC II and co-stimulatory molecules (Moore 
2001). 
As Av17 is derived from a parasite it is also fitting to find importance of IL-10 in its 
protection against asthma, as this is in accordance with reports on worm infection and asthma. 
IL-10 was described to modulate allergic immune responses in mice infected with the gut 
nematode Heligmosomoides polygyrus or the blood fluke Schistosoma mansoni (Kitagaki 
2006, Mangan 2004) shown by the use of IL-10 knockout mice or IL-10R, respectively. 
Also human studies point in this direction: The low response to the house dust mite (HDM) 
allergen Derp1 in skin prick tests of worm infected children in Gaboon could be linked to 
increased IL-10 production and no association between polyclonal IgE antibodies and skin-
test results was found (van den Biggelaar 2001). IL-10 is also crucial in mediating protection 
to food allergy by H. polygyrus as Bashir (2002) and co-workers could demonstrate by the use 
of aIL-10R antibodies.  
Of interest, some other studies demonstrate that helminth-induced protection against allergic 
disease can be independent on IL-10 (Trujillo-Vargas 2007) and propose a role for TGF-ß 
(Wilson 2005). TGF-ß was described in recent studies to have very distinct effects on asthma-
like disease. Application of antibody against TGF-ß in a mouse model resulted in suppression 
of pulmonary fibrosis but enhancement of OVA-induced AHR and had no significant effect 
on airway inflammation and eosinophilia (Alcorn 2007). Fattouh and co-workers monitored 
effects in a model of HDM-sensitization. They could induce airway inflammation and 
remodelling in mice treated with TGF-ß antibody and furthermore eosinophilic infiltrate was 
exacerbated and led to increased airway hyperreactivity (Fattouh 2008). TGF-ß is described to 
play an important role in the differentiation of Th17 cells. This might explain why TGF-ß 
sometimes revealed proinflammatory effects (Veldhoen 2006). 
In this work, transforming growth factor TGF-ß was analysed by two different techniques, 
ELISA and real-time-PCR. However, following cystatin treatment there was never any 
increase detected, but a tendency towards decreased TGF-ß mRNA amounts in lungs. 
Interestingly, in human studies, asthmatic patients provide higher levels of TGF-ß mRNA, 
reflecting fibrosis (Vignola 1997, Kenyon 2003). Hence, a decrease of TGF-ß in cystatin-
treated animals might reflect lowered fibrosis. Still, systemic induction of TGF-ß might bear 
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the potential to suppress allergic airway inflammation, as it has been described as a potent 
anti-inflammatory protein (Veldhoen 2006).  
4.1.3. Involvement of macrophages  
Thinking about a cell producing the mediator(s) and being the target of cystatin, the data 
obtained and recent studies in our lab (Hartmann 2003, Schoenemeyer 2001) speak for a 
crucial role of macrophages in the protective effect of filarial cystatin in the murine asthma 
model. Depletion of macrophages with clodronate liposomes two days prior to airway 
allergen challenge was found to completely ablate the anti-allergic effect of cystatin, 
including AHR, eosinophil infiltration, OVA-IgE and partly IL-4.  
Liposomes are artificially prepared lipid vesicles that can be used to encapsulate strongly 
hydrophilic molecules such as clodronate, solved in aqueous solutions. Clodronate 
(dichloromethylene-bisphosphonate, Cl2MBP) is a bisphosphonate that is usually prescribed 
as a bone resorption inhibitor and antihypercalcemic agent (en.wikipedia.org/wiki/ 
clodronate). Freely solved clodronate will not cross liposomal or cellular phospholipid 
membranes but after injection, liposomes will be ingested and digested by macrophages 
followed by intracellular release and accumulation of clodronate. At a certain intracellular 
concentration, clodronate induces apoptosis of the macrophage (www. clodronateliposomes. 
org). It is noteworthy to say that treatment with clodronate liposomes (MLV) mainly targets 
macrophages (because of the lipids used for preparing MLV) but also a small part of DC may 
be killed. However, all other potentially IL-10 producing cells (B cells, T cells, NK cells etc.) 
remain present (Van Rooijen 1994; Anthony 2006). 
In addition to abrogation of cystatin`s protective effects, macrophage depletion led to 
significantly diminished IL-10 levels in splenocytes of cystatin-treated animals, speaking for 
the macrophage as the main producer. Strikingly the major source of IL-10 in vivo (in 
humans) is the macrophage (Asadullah 2003).  
Macrophages have recently been of intense interest: They are important in the initiation of 
inflammation but also in the resolution of this response: Macrophages are necessary for the 
clearance of granulocytes and the elaboration of anti-inflammatory mediators contributes to 
dissolution of the inflammatory response (Zhang 2008). Macrophages can produce TGF-ß and 
thereby contribute to wound healing. Furthermore, they can produce IL-10 that may inhibit 
the synthesis and activation of many inflammatory cytokines (Mege 2006, O´Garra 2007). In 
addition, macrophages produce inflammatory tumor necrosis factor (TNF) that resolves 
inflammation by binding to death-domain containing TNF-R1 and induces cellular apoptosis 
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(Shen 2006). Today macrophages are broadly classified in two main groups, which are 
described according to static functional and phenotypic criteria (Mantovani 2005; Fig. 43).  
Classically activated macrophages (M1) are typically activated by IFN- and LPS or other 
TLR ligands leading to TNF secretion. They usually produce high levels of nitric oxide (NO) 
and exhibit low arginase activity but high CD86 expression. Classically activated 
macrophages are “effective APCs”, meaning that they stimulate T cell proliferation. M1 are 
also characterized by production of IL-12 and give rise to Th1 cells (Martinez 2008). 
Alternatively activated macrophages (M2) are further divided into M2a, M2b and M2c.  
When talking about alternatively activated macrophages (AAM) mostly M2a cells are referred 
to. They originate after exposure to IL-4 or IL-13 and are characterized by various markers. 
High expression of surface IL-4 receptor  chain (IL-4R) and mannose receptor (CD206) as 
well as expression of the newly identified markers macrophage galactose-type C-type lectin 
expression (mMGL1 and mMGL2) and IL-27 receptor (WSX-1 = IL-27R) are characteristic 
(Edwards 2006, Rückerl 2006). Intracellular markers for M2a AAM are high expression of 
FIZZ1 (found in inflammatory zone 1, resistin-like molecule ), Ym1/2 (secretory lectin, 
chitinase family) and arginase 1. Arginase expression restricts availability of L-arginine, a 
substrate for iNOS. This prevents NO production by these cells and shifts arginine utilization 
to production of polyamines and proline which are needed in wound-healing (Zhang 2008). 
M2a macrophages fail to stimulate T cell proliferation and do not express CD86 on their 
surface. This group of AAM has been closely associated with parasitic disease (Hesse 2001) 
and may provide immunity during helminth infections (Brys 2005, Anthony 2007). 
Macrophage characteristics can be influenced by glucocorticoides (IL-10 up), adenosine (TNF 
down, IL-10 up) and resolvins (derivatives of eicosapentaenoic acid, promote uptake of 
apoptotic cells) and the surrounding of IL-10 and TGF-ß. These macrophages are merged as 
M2b alternatively activated macrophages (Zhang 2008). 
In close proximity to immune complexes in combination with IL-1ß or LPS (Toll-like 
receptor ligands) the third group of AAM, the M2c or type II macrophages emerge. Type II 
macrophages express high levels of NO and CD86, low arginase activity and stimulate T cell 
proliferation (give rise to IL-4 and IL-10 secreting Th2 cells). Interestingly they produce a lot 
of IL-10 but no IL-12 (Anderson 2002a, b, c) and are described as strong anti-inflammatory 
cells (Gerber 2001). Currently they are best characterized on mRNA level by the markers 
sphingosine kinase-1 (SPHK1 or SK-1) and LIGHT (TNF superfamily 14). Of interest, in 
vitro studies revealed that SPHK1 catalyzes the production of sphingosine-1 phosphate, which 
is necessary for C5a-triggered, intracellular Ca2+ signals (Melendez 2004), might play a role 
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in retaining cell viability in endotoxin-stimulated MØ (Wu 2004) and controls overproduction 
of Th1 cytokines in T cells (Yang 2005). LIGHT can costimulate T cell responses (Tamada 
2000) and transmit costimulatory signals into T cells thereby enhancing activation in response 
to suboptimal TCR interactions (Shi 2002, Wan 2002). 
Type II macrophages have been suggested to play a role in exacerbation of visceral 
leishmaniasis where IgG-coated parasites can induce production of IL-10 from macrophages 
and allow disease progression (Miles 2005). 
In general M2 macrophages promote Th2-associated effector functions and play a role in 
resolution of inflammation through endocytic clearance, trophic factor synthesis and reduced 
proinflammatory cytokine secretion (Martinez 2008). The new cytokine IL-21 seems to 
augment alternative macrophage activation and Th2 response as shown in experiments with 
IL-21R-/- mice, having an attenuated Th2 response to N. brasiliensis, H. polygyrus or  
S. mansoni (Pesce 2006, Frohlich 2007). 
Figure 43: Overview of classically (M1) and alternatively (M2) activated macrophage populations. Stimuli to 
induce cells and main effector mechanisms of macrophages are indicated. 
Helminth infections are associated with induction of alternatively activated macrophages 
(Herbert 2004, Gordon 2003, Hesse 2001, Loke 2000, Pesce 2006, Anthony 2007). In murine 
models of filarial infection (Brugia malayi) the nematode-elicited macrophages express 
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phenotype characteristics of AAM and are potent suppressors of T cells proliferation (Nair 
2005). Potent suppressive AAM also arise with L. sigmodontis infection and the immune 
suppression seems to be independent of IL-10 and CTLA-4 but partially dependant on TGF-ß 
(Taylor M 2006). Anthony and colleagues could show in a model of H. polygyrus infection 
that in secondary infection with the helminth, memory cells in the gut produce IL-4 and lead 
to the induction of AAM expressing IL-4R and CD206. The protective Th2 immune 
response is mediated by AAM which impair larval parasite health and mobility through an 
arginase-dependent mechanism (Anthony 2006). AAM can contribute to fibrosis and repair at 
the site of injury which might be of considerable importance during helminth infection but 
could also be extended to other “wounds” (Martin 2005).  
However, also macrophages with suppressive activity that are not alternatively activated cells 
have been shown to be induced by injection of schistosome egg glycans. These F4/80+ +Gr1  
macrophages suppress T cell proliferation (Atochina 2001, Terrazas 2001). Furthermore 
schistosomes can modulate splenic macrophages to induce T cell anergy via a mechanism 
involving the costimulatory surface marker PD-L1 (Smith 2004). 
Also macrophages isolated from tumors (Mantovani 2002) and glucocorticoid-treated 
macrophages (Frankenberger 2005) have been reported to preferentially secrete IL-10. 
Another novel type of macrophage is defined by its state of activation. IFN--stimulated 
monocyte derived cells (IFN- -MdC) differ in mode of generation, cell surface phenotype 
and function from classically activated macrophages. They arise only in the presence of 
CD40L-expressing CD4 T cells, M-CSF and IFN- . Interestingly, they enrich co-cultured  
T cell populations for CD4+ + +CD25 Foxp3  Tregs by expansion of these cells and depletion of 
activated T cells. Furthermore, they express CD274 (PD-L1) but could not be shown to use 
this costimulatory pathway. Lymphocyte killing is cell contact and caspase dependent (Brem-
Exner 2008) and transferred cells can protect from colitis. 
Munn et al described a somewhat similar macrophage type derived of human PMBCs in 
presence of CD40L, IFN-  and M-CSF. However, these classically activated macrophages 
influence T cell function through IDO (Indoleamine-pyrrole 2,3-dioxygenase) - dependent 
mechanisms (IDO-mediated tryptophan depletion) and lead to T cell apoptosis (Munn 1999, 
1996). 
Although definitions of different functional phenotypes of macrophages have scientific and 
diagnostic value it is quite possible that macrophages are not static and that functional and 
phenotypic changes may be just an evolving shift of functional activities in response to 
regulatory oscillations in their environment (Stout 2004). 
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Cystatin treated macrophages still produce NO in vitro, however in vivo application of 
cystatin did not lead to measurable amounts of IFN- or other Th1 cytokines in situ (in the 
lung) or systemically, speaking against an effect on/via classical activated macrophages. 
In the setting of the analyzed asthma model the Th2 cytokines IL-4 and IL-13 can be found in 
mice suffering from asthma. Cystatin was found to mediate downmodulation of both these 
cytokines (especially IL-4) but nevertheless it is still feasible that in the beginning of 
treatment enough of these cytokines were present to alternatively activate macrophages. This 
would be in line with the fact that alternatively activated macrophages can develop after 
helminth infection (MacDonald 1998), are markedly cytostatic and prevent the proliferation 
of non-lymphoid as well as T cells. They have also been shown to reduce the proliferation of 
a Th2 cell clone in vitro (Allen 1998). AAM were found in the presence of filarial and other 
helminth infections (MacDonald 1998), where secretion of cystatin may also be found. 
Nonetheless, AAM have been described to have anti-inflammatory potential, for instance they 
are able to suppress T cell proliferation by secretion of the cytokines TGF-ß and IL-10 
(Goerdt 1999, Reyes 2007). Interestingly, Hoves and co-workers could show alternatively 
activated macrophages to mediate anergy and induce regulatory T cells (Hoves 2006). AAM 
found in filarial infections were also described to use a different mechanism to interfere with 
T cell proliferation, namely comprising a receptor-mediated mechanism and cell-cell-contact 
(Loke 2000). Alternatively activated macrophages could indeed bear the potential to mediate 
protection of inflammation as found by application of cystatin.  
Nevertheless in recent studies (T. Buhrke, unpublished observation), transcription profiling of 
murine macrophages after exposure to filarial cystatin revealed an up-regulation of IL-10 
expression, but no changes in expression of markers of alternative macrophage activation 
(Arg, FIZZ, YM1). 
Thus one of the other subpopulations of AAM might be generated in response to Av17 
treatment. Cystatin-treated macrophages seem to resemble type II–activated macrophages 
(Edwards 2006) or M2c. As described above, type II macrophages are effective producers of 
IL-10, mRNA of the Th1 cytokine IL-12 is completely diminished but NO production is still 
active. Although characterization of all these possibilities in detail is done by co-workers and 
is not a part of this work, it is still intriguing to speculate about type II macrophage induction 
by cystatin. Cystatin can not only induce IgG1 antibodies to form immune complexes, it has 
also been described to give a short stimulus of TNF- before IL-10 production in vitro 
(Hartmann 2002). This could be enough stimulus to replace the usual costimulator LPS. 
Furthermore Av17 may also bind to TLR4, thereby providing the costimulus, maybe also by 
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atypic binding, as Harnett (2006) could prove for another nematode immunomodulator, ES-
62.  
Macrophages have also been in the focus of other studies concentrating on asthma and / or 
helminth immunomodulation. Recently Niu and co-workers could unravel a novel pathway 
regulating inflammatory disease in the respiratory tract. They could show that airway 
inflammation with repeated exposure to inhaled antigen suppresses CD4 T cells and their 
effector response in the respiratory tract and that this suppression was not dependent on host 
lymphocytes, in contrast to Tregs described as mechanism for inhaled tolerance (Holt 1981, 
Akbari 2001, Ostroukhova 2004). Furthermore, suppression was antigen non-specific and 
associated with a marked expansion of TGF-ß1-expressing lung macrophages (Niu 2007). 
Smith and co-workers described, that infection with the trematode parasite S. mansoni 
prevents experimental colitis via a macrophage-mediated mechanism with strong infiltration 
of F4/80+CD11b+ -CD11c  macrophages into the colon lamina propria, which is transferrable to 
uninfected animals. So far, they excluded that the effect is mediated by alternatively activated 
macrophages via measurement of arginase in colon macrophages and use of IL-4/IL-13-/- that 
have defects in AAM (Smith 2007).  
Taken together, it seems quite likely that cystatin treatment indeed leads to induction of  
IL-10-secreting type II macrophages that mediate protection of allergic airway inflammation. 
4.1.4. Role of regulatory T cells (Tregs)  
Another target cell of cystatin might be regulatory T cells. Tregs have been suggested to play 
a major role in several settings of protection against asthma (Hawrylowicz 2005a, Stock 
2006) and especially in protection by parasitic worms (Kitagaki 2006, Wilson 2005). Leech 
and colleagues could show in a Derp1 model that transfer of CD4+CD25+Foxp3+ Tregs led to 
resolution of allergic airway inflammation in an IL-10 independent way (Leech 2007). Of 
special interest, there have been human studies suggesting that allergy is due to a lack or 
functional insufficiency of these immune cells (Hartl 2007, Lin 2008). 
In an animal model Wilson could transfer protection by MLNC transfer, but also by MLNC 
derived from IL-10 knockout mice. He found increased levels of IL-10 in C57BL/6 Derp1 
mice and increased, but not significantly, TGF-ß in BALB/c OVA mice in BALF (Wilson 
2005). 
Interestingly, the protection of asthma by transfer of OVA-stimulated CD4+ T cells was only 
effective when cells were derived from Hp/OVA treated mice, not from Hp or OVA treated 
mice and dependent on IL-10 (Kitagaki 2006). Furthermore, T regulatory cells obtained from 
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O. volvolus infected patients secrete IL-10 and TGF-ß and suppress proliferation (Satoguina 
2002). This indicates controversial data on the involvement of IL-10 in Treg suppression in 
asthma. 
Up to now, Treg cells have been roughly divided into natural Tregs (characterized by CD25, 
CD4 and Foxp3 expression), Tr1 cells characterized by secretion of unusually high levels of 
IL-10 and lower levels of TGF- (Groux 1997, Buer 1998), and Th3 cells described to 
produce large amounts TGF- and thought to be related with mucosal immunity and IgA 
production (Chen 1994, Fukaura 1996, Powrie 1996, Hafler 1997). 
In this work a population of natural Treg cells was analyzed. The effector/memory-like 
regulatory T cell subset is characterized by the expression of CD25, CD4 and the integrin 
E7 (CD103) and was shown to exhibit a particular high suppressive capacity (Lehmann 
2002), especially in the context of H. polygyrus infection (Rausch 2008). In addition control 
co-stainings with Foxp3 (forkhead box transcription factor p3) ensured that Treg cells and not 
T effectors were analyzed.  
Filarial cystatin was found to induce small but significantly elevated numbers of Treg cells in 
the lung draining lymph nodes, or in other words at the site of inflammation. Consequently, 
importance of this increase was analyzed by depletion of Treg cells. Treg cells were depleted 
with high efficiency by application of CD25 antibodies in the asthma model 5 days before 
airway challenges. However, lack of Treg cells did not convert the protective effect of 
cystatin completely. Depletion of Tregs revealed only a trend of restoration of eosinophil 
numbers in the lung and no significant increase in AHR, arguing for only a partial 
involvement of Treg cell in Av17-protection.  
However, one could argue that conversion of the protective cystatin effect was only partly 
because Treg cells were depleted by antibody application. Currently CD25 application to 
deplete Treg cells is discussed controversly. Kohm et al suggest, that Treg cells are not 
depleted but CD25 expression is simply downmodulated by application of antibodies. His 
work refers mostly to the use of the depleting CD25 antibody named 7D4 which has indeed 
produced bigger proportions of CD25 low cells but not a lack of them (Kohm 2006). However, 
Stephens and co-workers describe a significant effect of the depleting antibody PC61 as do 
Zelenay and Demengeot (Stephens 2006, Zelenay 2006). They could present convincing data 
that PC61 application does not only lead to functional inactivation but really lack of Treg 
cells. In the present work PC61 was used, speaking for efficient depletion of Treg cells as also 
observed in control FACS stainings. 
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Nevertheless, to be absolutely sure that no Treg cell is left, DEREG (depletion of regulatory 
T cell) mice would be the experiment of choice. These are chromosome-transgenic mice 
expressing a diphtheria toxin (DT) receptor-enhanced green fluorescent protein (GFP) fusion 
protein under the control of the foxp3 gene locus, allowing selective and efficient depletion of 
Foxp3+ Treg cells by DT injection (Lahl 2007). However, it still remains to be established if 
our asthma model will work in these mice and if Treg cell can be depleted throughout the 
whole model. 
Hence, cystatin has an effect on the recruitment of regulatory T cells no matter if they are 
crucial for protection or not. It is possible that changes occurring in other Av17-target cells, 
namely the macrophages, could create a milieu attracting Treg cell migration, proliferation or 
production. Furthermore, as our depletion experiments revealed that Treg cells contribute to 
the lowering of eosinophil numbers and OVA-specific IgE production, it might be that IL-10–
independent Treg cell functions have a role in the anti-allergic effect of cystatin (Fehervari 
2004, Miyara 2007).  
4.1.5. Potential role of B cells 
Interestingly, regarding other infections such as schistosomiasis or toxoplasmosis, B cells or 
Th1 cells are shown to be the relevant IL-10 sources and mediate suppression of anaphylaxis 
(Mangan 2004) or host protection (Jankovic 2007). A number of studies has been performed 
in the past, directing to an important role for regulatory B cells (Breg) in anaphylaxis, EAE 
(experimental autoimmune encephalomyelitis) and other inflammations (Mauri 2008).  
However, B cell depletion has to be done in a very careful approach, as there are reports that 
B cell depletion and B cell deficient mice would interfere with the model (Hamelmann 1997a, 
b). A possibility to analyze B cells would be the transfer of B cells derived from spleen, a 
method described by Smits (2007) in the context of transfer of schistosome-dependent 
protection of airway inflammation. Alternatively, intracellular IL-10 staining of B cells could 
be performed. However, in a recent report, B cell depletion shortly before challenge with 
IgM was shown to be feasible, as Mangan (2006) could demonstrate influence of B cells in 
male schistosome-mediated protection of AHR and lung inflammation and described no 
influence per se on this model, leaving another option, although influence on sensitization 
might be quite drastic.  
For the future, it seems very sensible to perform experiments to address involvement of these 
cell populations in the context of filarial cystatin, but maybe better in disease models that do 
not directly depend on antibody production. 
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4.1.6. Possible receptors translating Av17 signals 
As the results obtained with Av17 in the airway hyperreactivity model point to the 
macrophage as the main target cell of Av17 it is also necessary to speculate on possible 
receptors the proteinase inhibitor cystatin could address. There are several hints pointing to an 
involvement of innate immunity receptors such as scavenger or Toll-like receptors. 
Scavenger receptor CD36 is one potential candidate. It is predominantly expressed on 
macrophages, platelets and endothelial cells (Adachi 2006). Of particular interest, CD36 has 
been described as the receptor for the cell adhesion protein PfEMP1 of the malaria parasite 
Plasmodium falciparum and binding of PfEMP1 to CD36 leads to the induction of IL-10 
(Urban 2001) which would fit to effects seen with Av17. Furthermore CD36 is linked to 
uptake of apoptotic material and thereby modulating DCs to a “passive” or “alternative” 
activation state, which could influence inflammatory responses (Urban 2001). Another 
possibility might be TGF-ß receptor II. Human cystatin has been shown to physically interact 
with the TGF-ß receptor, thereby antagonizing TGF-ß signaling in cancer cells (Sokol 2004). 
As TGF-ß is found to be up-regulated in asthmatic lungs in human patients and 
downmodulated in murine lungs treated with Av17, one could hypothesize that cystatin 
competes with host TGF-ß and thereby reduces asthma pathology, in addition to IL-10 
induction which would be required to block for example IgE production. Furthermore, other 
pattern recognition receptors (PRR) as TLRs (Toll-like receptors) might be addressed. 
Regarding helminth infections three distinct TLRs have been described to be addressed so far: 
TLR2 (schistosomal lyso-PS; filarial AvTropo), TLR3 (schistosome egg dsRNA) and TLR4 
(filarial ES-62) (van der Kleij 2002, Aksoy 2005, Goodridge 2005a). Of interest, the PC 
containing secreted glycolipid ES-62 targets TLR4 in an atypic manner compared to the 
classical ligand LPS. This was shown by the use of HeJ mice in which LPS cannot bind or 
signal via TLR4 because of a point mutation in the receptor. Nevertheless ES-62 signaling is 
still functional (Harnett 2006). It is possible that cystatin might trigger a similar cascade. 
Another interesting aspect is the inducible T cell costimulatory receptor CD137 (4-1BB). This 
member of the TNFR-family normally addresses CD8 T cells, however experimental 
costimulation of CD137 (by agonistic antibodies) was shown to inhibit Th2-mediated AHR, 
eosinophil recruitment and allergen-specific antibody production. CD137 is expressed on 
activated T cells, natural killer cells, NKT cells and Tregs and its natural ligand CD137L 
(4-1BBL) is found on APCs (B cells, macrophages and DCs). CD137 stimulation increases 
Treg numbers but the protective effect is not blocked by application of PC61 (Sun 2006). So 
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far, it is up to speculation if cystatin treated macrophages increase CD137L expression or if 
cystatin can directly bind to CD137. 
Finally, it would also be feasible that cystatin binds to the FcR as a complex with IgG1 
antibodies and thereby generates immunmodulatory IL-10 producing Type II macrophages. 
This is strongly suggested by in vitro data obtained by colleagues (C. Klotz, P. Burda) and 
discussed in detail above (see type two macrophages). 
4.1.7. Proteinase inhibitor function of Av17 and role of DCs 
A. viteae cystatin has been described to be a potent cysteine proteinase inhibitor (Hartmann 
2003). Therefore one could also assume that the proteinase inhibitor function of cystatin is 
needed for its protective effect. Layton and colleagues observed therapeutic effects of the 
broad-spectrum cysteine proteinase inhibitor E64 on allergic lung inflammation. E64 had 
mainly effects on extracellular cathepsins and thereby influenced migration and proliferation 
of allergen specific T cells. Furthermore, it was postulated that E64 could block or inhibit 
cell-cell interactions, regulate cell adhesion molecules and cytokine, chemokine and death 
receptor ligands by blocking proteinases needed for the formation of these surface molecules. 
However, in contrast to data obtained with Av17 application, they did not show any influence 
on IgE levels, mucus production or airway hyperreactivity (Layton 2001). In addition, in vitro 
studies indicate, that IL-10 production after cystatin stimulus is found also with a mutated 
Av17 (mAv17, no proteinase inhibitor function). On the other hand, first therapeutic studies 
with mAv17 in the asthma model point in the direction that AHR is differentially regulated by 
cystatins with or without inhibitor function.  
In recent studies protease-activated receptors (PARs) have been suggested to provide a novel 
pathway by which proteases affect innate immune responses (Shpacovitch 2007). The  
G-protein-coupled PARs can be activated by proteases via proteolytic cleavage and are found 
on epithelial cells, endothelial cells and leukocytes. Bacterial proteases and allergens with 
protease-activity have been shown to be able to activate distinct PARs and to be involved in 
allergic diseases (Reed 2004). Thereby, it might be possible that cystatin treatment addresses 
PARs by inhibiting their activation because proteases are blocked. In addition, eosinophils 
and mast cells were shown to express PARs on their cell surface. Addressing these receptors 
leads to release of mediators and thereby pathologic changes in tissues (Bolton 2003, Dugina 
2003), which might also be prevented by cystatin treatment. 
Filarial cystatin has been shown to efficiently block cathepsins involved in antigen processing 
(Schoenemeyer 2001). In this context it might be quite promising to investigate Av17 effects 
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on dendritic cells (DC) in detail. First studies (diploma thesis of J. Hagen, 2007), revealed a 
phenotype characterized by MHCIIlow low int CD40  and CD80/86 . Hence, they closely resemble 
immature DCs, although IL-12 secretion could be detected. Immature DCs or DCs that do not 
get proper maturation signals after antigen procession are described to induce anergy in  
T cells and thereby may lead to induction of tolerance (Lutz 2002). It is possible that cystatin 
achieves this immature DC state by interaction with cystatin C and by this, inhibition of the 
cysteine protease cathepsin S (needed for antigen procession and transport to cell surface). 
Still no information is so far available on the priming of T cells by Av17 pulsed DC. 
Furthermore, Av17 effects on other APCs, as macrophages, reveal a completely different 
picture with induction of TNF- followed by massive IL-10 production (Hartmann 2002). 
Interestingly, in general, stimuli associated with Th2 response are often less strong inducers of 
DC maturation (DC2) than the ones associated with Th1 response induction (DC1). Immature 
DCs may induce tolerogenic immune response and induce T cells to become Tregs (Mahnke 
2002). So far only a component of Schistosoma mansoni (lyso-PS) has been shown to 
effectively stimulate DCs to make IL-10 producing Tregs (van der Kleij 2002). 
4.1.8. Mechanisms of immunomodulation by other helminth components 
A. viteae cystatin seemingly provides a novel mechanism of immune modulation, which is 
different from other well-described helminth immunomodulators. In Schistosoma mansoni 
eggs a phosphatidylserine with specific chain length is expressed. It engages TLR2 expressed 
on dendritic cells, which in turn induces IL-10–producing regulatory T cells (van der Kleij 
2002). Furthermore, schistosomes express 'self glycan' antigens that are recognized by lectin-
receptors on host DCs, whose principal function is thought to capture self-glycan antigens and 
generate regulatory T cells to induce tolerance to these antigens. Thereby self-glycan antigens 
of schistosomes may deceive the host immune system to their own benefit. The host protects 
itself against damage by down-regulating helminth-induced Th2 immune responses, and may 
thus simultaneously be protected against excessive Th2 cell-mediated allergic responses (van 
Die 2006).  
In addition S. mansoni eggs secrete a protein into host tissues that binds certain chemokines 
and inhibits their interaction with host chemokine receptors and their biological activity 
(smCKBP), thereby suppressing inflammation in several disease models (Smith 2005). 
Only recently, a secreted glycoprotein of the filariae A. viteae (ES-62) was described to 
inhibit FcRI-mediated mast cell responses by forming a complex with TLR4. This resulted in 
the sequestration of protein kinase C-, a molecule important for mast cell activation via 
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coupling of FcRI to phospholipase D (Goodridge 2005b, Melendez 2007). Application of 
ES-62 could stop mast cell-dependent hypersensitivity in skin and lung. In addition, ES-62 
has effects on B and T cells and APCs (DC, MØ) (Wilson 2003, Marshall 2005, Whelan 
2000, Goodridge 2001). Furthermore ES-62 was shown to suppress collagen-induced arthritis 
(CIA) (McInnes 2003) and this was done at least partly by disruption of B cell activation and 
modulation of Toll-like receptor signaling on DCs and macrophages, influencing their 
maturation and cytokine production and not dependent on IL-10 (Goodridge 2004, 2005b). 
The group of deMacedo, working on a protein extract of the tape worm Ascaris suum  
(PAS-1), was able to show that their component inhibits allergic airway inflammation (Lima 
2002, Itami 2005) and anaphylaxis (deMacedo-Soares 2007) and that immunosuppression is 
dependent on IL-4 and IL-10 (Souza 2004). PAS-1 also led to IL-10 (and in some settings to 
TGF-ß) induction and could prime for regulatory T cells (deMacedo-Soares 2007). In addition 
PAS-1 treated macrophages produce IL-10 and TGF-ß (Itami 2005). 
Further studies on the molecular mechanisms of immune modulation by filarial cystatin, such 
as the signaling pathways involved and the domains of cystatin responsible for the described 
effects are currently under way. Preliminary results indicate that mitogen-activated protein 
kinases are involved in the cystatin-induced modulation of macrophages, which is in line with 
recent data showing that inhibitors of mitogen-activated protein kinases may be suitable 
targets for anti-inflammatory therapy of asthma (Chialda 2005). 
64 
Discussion 
In conclusion, the data obtained on Av17 application in an asthma model, clearly suggest that 
the broad-acting anti-inflammatory activity of cystatin, which supposedly protects the worms 
from inflammation triggered by worm-derived components, might be exploited for the 
treatment of immune-related diseases. It selectively mimics the advantageous properties of a 
parasite infection without entailing its undesired side effects. Furthermore, data indicate that 
its protective effect is mediated by IL-10 secreting macrophages, which might be of the 
alternatively activated type II macrophage family (Figure 44). 
 
Figure 44: Effects of filarial cystatin (Av17) in vivo in a murine model of asthma linked to state of the art in 
vitro data: Recent studies revealed inhibition of cathepsins L and S, down-modulation of MHC class II (MHCII) 
and costimulatory molecule CD86 as well as strong induction of interleukin 10 (IL-10) and a short induction of 
tumor necrosis factor  (TNF ). The present in vivo data document a complete block of airway inflammation, 
airway hyperreactivity (AHR), allergen-specific IgE and local and systemic allergen-specific IL-4. Furthermore 
a systemic induction of cystatin-specific IL-10 was found (Av17-specific IL-10). In addition cystatin treatment 
led to increase in Treg numbers and it is hypothesized that macrophages are alternatively activated by TNF- 
and Av17-IgG1-immune complexes binding to Fc receptor to become IL-10-secreting type II macrophages. 
4.2. Influence of filarial cystatin on atopic dermatitis 
Filarial cystatin could be demonstrated to provide protection of allergic airway inflammation 
in a murine asthma model, probably via IL-10 induction in macrophages (Schnoeller 2008). 
Application of cystatin in a murine model of atopic dermatitis (A.D.) now was moving from a 
strictly Th2 dependent allergy model to a mixed Th1/Th2 model. The concept of the 
pathobiology of atopic dermatitis involves a systemic Th2 response in addition to a biphasic  
T cell response in the skin with Th2 cells in acute A.D. and Th1 cells in the chronic phase 
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(Leung 2004). Application of filarial cystatin mediated profound amelioration of eczema 
formation in treated mice.  
First, the clinical skin score, indicating the severity of inflammation, was nearly abolished 
after cystatin treatment. The stop of inflammation was also reflected by decreased epidermis 
thickness and, more importantly, by significantly decreased numbers of CD4 T cells and mast 
cells in skin. CD4 T cells are strongly linked to atopic dermatitis, mediating the inflammation 
by secretion of the cytokines IL-4 mainly in the acute phase but also IFN- and TNF- in the 
chronic phase of the disease (Fiset 2006). Thereby downmodulation of these cells reflects an 
improved inflammation on cellular level. Mast cells are known to express FcRI, bind IgE and 
degranulate in response to allergen, thereby releasing histamine, cytokines and chemokines. 
Mast cell degranulation in skin leads to erythema, edema and itch (Prussin 2006), which 
would also promote skin inflammation (Matsuda 1997, Dahten 2008). Therefore, the reduced 
mast cell numbers found after cystatin-treatment clearly point to a block of cutaneous 
inflammation. Interestingly mast cells are described to produce IL-25 (Ikeda 2003), a member 
of the IL-17 family, which is supposed to be strongly involved in atopic dermatitis (Toda 
2003, van Beelen 2007). The role of IL-17 in Av17-treatment will be investigated in detail in 
the future. 
Apart from differences in cell recruitment, sensitization was clearly affected by application of 
cystatin, leading to decreased levels of allergen-specific IgE. Although this did not result in 
decreased degranulation of RBL cells, in contrast to what was found in the asthma model, 
lower IgE levels and lowered mast cells numbers could still account for less allergic 
inflammation. However, this might also indicate that in this model of atopic dermatitis 
blocking IgE is not sufficient to suppress eczema, especially as a decrease in OVA-IgE 
without mast cell down-regulation, as seen with control protein DHFR, led to aggravation 
instead of amelioration. Nevertheless, in the model used in this work, the sensitization phase 
was described to be essential for induction of dermatitis (Dahten 2008) emphasizing the role 
of IgE in the early phase of inflammation. 
Furthermore, cystatin application clearly altered cytokine patterns in systemic and local 
analyses. Allergen-specific cytokine production was systemically down-modulated, 
accounting for a lowered Th2 response, and no Th1 cytokines were measurable, arguing 
against a mere switch to Th1 to stop Th2 in the early phase (Wang 2007). Local cytokine 
measurements in patched skin pointed out, that the dermatitis-associated cytokines IL-4,  
IFN- and IL-10 were strongly downmodulated after cystatin treatment but anti-inflammatory 
TGF-ß was nearly 20 fold upregulated. These findings were in contrast to Av17-treatment in 
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the asthma model, as TGF-ß was downmodulated in BALF and described to be detrimental in 
lungs, pointing to different effects of the anti-inflammatory cytokine depending on the model 
and the site of inflammation, respectively. However, Lan and co-worker could show that 
TGF- in A.D. is produced by keratinocytes after tacrolimus treatment and thereby 
presumably involved in down-regulation of inflammation in eczema regions (Lan 2004). 
Apart from that, TGF-ß was found to be responsible for curing of skin lesions in the murine 
NC/Nga atopic dermatitis-model (Sumiyoshi 2002). Hence, such strong increase of TGF-ß in 
skin of Av17-treated mice seems feasible to mediate the protective effect but this will have to 
be proven in the future by application of TGF-ß-blocking antibodies.  
Another aspect of cystatin treatment in atopic dermatitis might be Tregs. However, Treg 
numbers in skin-draining inguinal lymph nodes (ILN) were not altered by cystatin application. 
Interestingly, the Treg numbers in mesenteric lymph nodes were found to be “restored” to 
naïve levels. The role of Tregs in atopic dermatitis is contradictorily discussed. There are 
studies indicating a clear lack of CD4+ + +CD25 Foxp3  Treg cells in human A.D. skin samples 
(Verhagen 2006), whereas other studies claim that Treg numbers are even increased in human 
eczema but loose their immunosuppressive capacity (Ou 2004). However, in the treatment 
with cystatin, Tregs do not seem to be the main mediators of protection, as Tregs in 
mesenteric lymph nodes will probably not directly improve skin inflammation and Foxp3 
mRNA measured in eczema regions gave no clear hints towards an increase or decrease. 
Nevertheless, cystatin seems to be capable to restore at least partly, in several compartments, 
a possibly disrupted Treg network.  
Apart from increase of TGF-ß in skin tissues other mechanisms of cystatin seem feasible. In 
the asthma model our group could show that cystatin effects are strongly dependent on IL-10 
producing macrophages (Schnoeller 2008). Unfortunately depletion of macrophages over 10 
weeks (duration of the dermatitis model) can hardly be achieved without the danger of 
animals dying due to infections, and more importantly altering the model. Antibodies against 
IL-10 receptor are also not feasible in this model, as local IL-10 reduction (in skin) improves 
inflammation itself (Sakamoto 2004) and a 10 week treatment again would be too “unhealthy” 
for the animals. Nevertheless, it is still possible that cystatin-specific IL-10 (which was found 
in spleens) downmodulated the systemic inflammatory response in a similar way as in the 
asthma model, without increasing IL-10 mRNA in skin, as IL-10 was also not increased in 
BALF.  
Another feature of cystatin that has to be taken into account regarding atopic dermatitis is its 
proteinase inhibitor capacity. Many allergens are proteinases (for example the main allergen 
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of house dust mite Derp1 is a group 1 allergen, a cysteine proteinase, Thomas 2002). Already 
starting with sensitization it has been shown that enzyme activity can be very important for 
the efficiency of this process (Harris 2004). A protease inhibitor applied in a Derp1 
sensitization model led to inhibition of CD 23 cleavage from human B cells and significantly 
reduced HDM-induced permeabilization of the epithelial barrier (John 2000). Other cystatins, 
like cystatin A derived from human sweat, were shown to inhibit Derp1 induced IL-8 
expression by human keratinocytes, thereby stopping its allergenic potential (Kato 2005). 
However, in this model OVA was used as allergen and ovalbumin is not a proteinase but a 
non-inhibitory serine protease inhibitor. Nevertheless, as the dermatitis model does not 
function under sterile conditions (personal communication A. Dahten), other allergenic 
components might be important, and they could indeed include proteases.  
Recently the cytokine IL-31 was associated with atopic dermatitis. Bilsborough and 
colleagues could show that IL-31 is not only expressed by CLA (cutaneous lymphocyte 
antigen) positive T cells but that expression in keratinocytes and macrophages also correlates 
with severity of disease (Bilsborough 2006). It is quite possible that cystatin blocks IL-31 
secretion by altering / differentially activating macrophages or blocking secretion in CLA- 
T cells but these analyses have to be done in the future. 
Interestingly, another A.D. model makes use of IL-4 transgenic mice, in which the cytokine is 
expressed in the basal epidermis, using a basal keratinocyte-specific keratin 14 promoter 
(Chen 2004). It is possible that the downregulation of allergen-specific IL-4 found in Av17 
treated animals (as also observed in the asthma model) contributed to amelioration. This 
might be due to the fact that IL-4 can prevent apoptosis of inflammatory cells in the dermis, 
as it was shown by Trautmann et al (2001), and thereby inflammatory cells persist. 
Another interesting parameter associated with atopic dermatitis, and as well as with asthma, is 
TSLP (thymic stromal lymphopoietin). This IL-7-like cytokine is expressed by keratinocytes, 
triggers DC-mediated Th2 responses and could be correlated with severity of A.D. (Liu 
2006). However, so far cystatin treatment did not lead to differences in TSLP-staining of skin 
sections.Taken together this work provides evidence that cystatin application in a murine 
model of dermatitis clearly abolishes eczema formation in challenged skin. The most 
outstanding alterations were found on cell recruitment and cytokine production. Av17-
treatment induces strong up-regulation of transforming growth factor-ß (TGF-ß) in patched 
skin revealing a probable mechanism of amelioration (Figure 45). However, so far no defined 
cell population could be linked to the enhanced TGF-ß production. Thus it is quite possible 
that, as in Av17-treatment in asthma, Av17-specific IL-10 production and thereby differential 
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cell recruitment and reduced allergen-specific Th2 cytokine secretion could have led to cure 
eczema, leaving TGF-ß increase as a result of induced wound healing. 
Figure 45: Effects of filarial cystatin (Av17) application in a murine model of atopic 
dermatitis. Av17-treatment abolished atopic eczema, downmodulated mast cell and 
CD4 T cells in skin and abrogated allergen-specific IgE production. In cured mice 
systemic IL-10 production in response to Av17 stimulation was strongly increased and 
TGF-ß levels in skin dramatically upregulated. However, so far it is not clear if these 
effects are mediated by IL-10 producing macrophages or by unknown cells secreting IL-
10 or TGF-ß. 
4.3. Worm infection and allergy: Comparing the influence of H.polygyrus in an asthma 
        and a dermatitis model 
Infections with parasitic worms have been demonstrated to potentially suppress allergic and 
inflammatory immune responses (Maizels 2004, Fallon 2007). However, there have also been 
some reports on aggravation of allergy in human patients and laboratory animals, which were 
so far linked to chronicity and severity of infection. Mouse models indicated, that only acute 
infection with Trichinella spiralis protects in a murine model of DTH, whereas a chronic 
infection with H. polygyrus does not provide amelioration. Interestingly in both infections 
strong IL-10 production was found, pointing in the direction that effects depend on the 
context of its release (Boitelle 2005). 
Still, different outcome of parasite infection and allergy might not only depend on state 
(chronic or acute) and worm species but also on allergic disease and timing of helminth 
exposure (in utero, in first year, in adults) (Cooper 2006) as well as biology or localization of 
the parasite. 
The present work provides evidence that modulation of immune responses by the 
gastrointestinal (GI) nematode H. polygyrus seems to be restricted to mucosa-associated 
tissues. Thus, infecting animals in an asthma (mucosa) and a dermatitis (cutaneous) model 
revealed a beneficial effect of the GI nematode H. polygyrus on airway inflammation but not 
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in allergic skin lesions. H. polygyrus is a natural murine parasite with strictly enteric life 
cycle. 24-72h after inoculation third-stage larvae enter the wall of the small intestine and 
migrate into the muscularis externa beneath the mucosa. After 8-9 days adults emerge into the 
lumen and establish chronic infection in many strains of mice (Gause 2003). H. polygyrus 
induces a Th2 polarized immune response particularly in the MLN, blood eosinophilia and 
elevated levels of polyclonal serum IgE and IgG. 
In the present work, infecting mice with H. polygyrus, interfered with allergic airway disease 
probably using several mechanisms: H. polygyrus infection significantly reduced the 
recruitment of inflammatory eosinophils into the lungs, thereby the release of effector 
molecules that lead to tissue damage (Trivedi 2007, Rothenberg 2006) can be prevented. 
However, total cell numbers in BALF were not significantly altered, which was due to an 
increase in macrophages in the worm–infected animals. The increase in macrophages might 
have important functions in the amelioration of inflammation by helminths, as it is shown that 
macrophages provided protection in a colitis model (Smith 2007). Furthermore also Mangan 
and colleagues observed an increase in BAL macrophages within worm infection in an 
ameliorated asthma model (Mangan 2006). However, depletion of macrophages was not 
performed in our model, as macrophage depletion in Mangan´s setting did not lead to 
reversion of protection by Schistosoma mansoni males (Mangan 2006). 
In contrast to the asthma model, H. polygyrus infection in the dermatitis model did not 
interfere with induction of eczema, reflected by high clinical skin scores and increases in 
thickness of epidermis. Still in skin sections, decreased cell numbers in skin lesions of OVA-
treated and H. polygyrus-infected (OVA/Hp) mice, with respect to CD4+ + and CD8  T cells, 
were detected. In contrast, mast cells showed significantly rising infiltrations into the eczema 
region in OVA/Hp-animals. The recruited mast cells probably contributed to the aggravation 
of eczema in OVA/Hp-mice, as they release soluble mediators involved in allergic reactions 
(Averbeck 2007). In this regard, it is interesting to note that mast cells are described to 
produce IL-25 (Ikeda 2003), a member of the IL-17 family, which is supposed to be strongly 
involved in atopic dermatitis (Toda 2003, van Beelen 2007). The interleukin 17 family 
consists of at least 5 homologues to the primarily described IL-17A (Cooke 2006, Zaccone 
2008). IL-17A (or simply IL-17) is considered to be a proinflammatory cytokine. It is secreted 
by CD4 T cells, NK, CD8 and -T cells. IL-17A and IL-17F (IL-25) are specifically linked 
to the new Th17 lineage, which has a role in MS (multiple sclerosis), RA (rheumatoid 
arthritis), SLE (systemic lupus erythematosus) and psoriasis. IL-25 is produced by activated 
Th2 cells (Fort 2001) and mast cells (Ikeda 2003). It can induce the expression of chemokines 
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important for eosinophil and basophil recruitment (Fort 2001, Hurst 2002, Pan 2001), thereby 
amplifying the Th2 responses. Inhibiting IL-25 by soluble IL-25 receptor inhibits antigen-
induced eosinophil and CD4+ T cell recruitment into airways (Tamachi 2006). Administration 
of IL-17 members A, B, C, D and F leads to neutrophilia. IL-17D (IL-27) was first classified 
as a member of the IL-12 family. Its major function seems to be to limit Th17 effectors 
(Batten 2006, Weaver 2007). 
Koga and colleagues could observe that human A.D. patients had increased Th17 cells 
numbers secreting IL-17 in peripherial blood and associated with severity of disease. In 
addition, IL-17 producing cells were found to be enriched in eczema skin sections (Koga 
2008). In future studies IL-17 secretion and Th17 cells will be important and exciting features 
to investigate, especially as worm infections (trichuris) and gut immunity have already been 
linked to IL-17E (= IL-25) (Owyang 2006). 
Hence, recruitment of cells differed significantly in the two allergy models and could 
reasonably have accounted for the different outcomes of disease progression.  
Furthermore, H. polygyrus infection showed significantly decreased levels of allergen-specific 
IgE in both allergy models, probably resulting in less efficient sensitization of mast cells and 
basophils (Bradding 2006). However, the degranulation of a basophil cell line (RBL) 
sensitized with sera of OVA/Hp-mice was not reduced. This might be due to extremely 
increased total IgE levels in the OVA/Hp-group in the asthma and dermatitis model. Total IgE 
might have led to unspecific cross-linking of IgE receptors on RBL cells. Another explanation 
might be that OVA-specific IgE in the dermatitis model was bound by mast cells that 
massively infiltrated the skin and was therefore not measurable in sera. Thus, the decreased 
numbers of OVA-IgE in the dermatitis model might be due to a higher proportion of cell-
bound IgE and not lowered production of IgE by plasma cells.  
Interestingly, others did not find reduced OVA-specific IgE levels by nematode infections but 
still clearly ameliorated airway inflammation (Wilson 2005, Kitagaki 2006). Wilson and 
Kitagaki investigated settings with either completely established infection, meaning adult 
worms at the time point of first sensitization, or infection after sensitization phase. In contrast, 
in the present work mice were infected on the day of first sensitization. Therefore, it can be 
presumed that the inhibition of allergen-specific IgE is not essential for the amelioration of 
allergy by parasitic nematodes and that it is dependent of the time point of infection if 
allergen-specific antibody levels are decreased.  
Another important point is the influence of H. polygyrus infection on cytokine production. 
Comparing both models, the Th2 cytokines IL-4 and IL-10 in response to allergen-stimulation 
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were systemically decreased in spleens of OVA/Hp-mice in the asthma model. In contrast, 
spleen cell cultures of the OVA/Hp-group in A.D. did not show downregulation of allergen-
specific IL-4, IL-5 or IL-10. Interestingly, both models showed increased systemic IL-4, IL-5 
and IL-10 levels in response to parasite-antigen stimulation. Hence, only in the asthma model 
allergen-specific Th2 cytokine production was inhibited and in both approaches,  
H. polygyrus-infection resulted in an overall parasite-specific Th2 milieu. It is possible that 
the downregulation of allergen-specific IL-4 found in the asthma model (and also observed in 
Av17 treated animals in the asthma model) contributed to amelioration. In contrast, in the 
A.D. model, upregulated IL-4-levels could prevent apoptosis of inflammatory cells in the 
dermis and thereby inflammatory cells might persist (Trautmann 2001), accounting for 
aggravation of inflammation. 
One key mediator responsible for the downregulation of asthma might be the anti-
inflammatory cytokine IL-10. Gastrointestinal helminths are able to induce mucosal T cells 
(CD4, CD8 and also lamina propria cells) to make Th2 cytokines but also IL-10 and TGF-ß 
(Weinstock 2006). It has been shown, that systemic production of IL-10 can interfere with the 
development of airway hyperresponsiveness and allergic inflammation (Romagnani 2004, Fu 
2006). Thereby, IL-10 modulates Th2 responses by suppression of allergen-specific IgE 
production and concomitant induction of non-inflammatory antibody isotypes, by reduction of 
pro-inflammatory cytokines released by mast cells, basophils and eosinophils and by indirect 
interference with Th2-associated phenomena such as mucus production (Urry 2006, Taylor A 
2006). Thus, IL-10 is capable of redirecting pathologic allergic responses by a broad range of 
suppressive mechanisms. The importance of the constantly secreted IL-10 in helminth-driven 
modulation of allergic responses has already been shown in reports of infection with  
H .polygyrus or the blood fluke Schistosoma mansoni (Kitagaki 2006, Mangan 2004). 
However, systemic parasite-specific IL-10 production in the dermatitis model could not 
inhibit inflammation in skin. It is possible, that in this model the, relative to the asthma model, 
lower Hp-specific IL-10 levels were not sufficient to ameliorate disease but did alter 
infiltration of cells as indicated by reduced CD4 and CD8 T cells in skin.  
However, it is also cogitable that the IL-10 producing cells could not migrate to the “right” 
site (draining lymph node) or, as indicated in the Av17 dermatitis experiments, IL-10 is not as 
important as TGF-ß levels in patched skin. In addition, it has been described that IL-10 in skin 
lesions may be detrimental instead of ameliorative (Simon 2007, Sakamoto 2004). 
As mentioned before, TGF-ß has also been described as a potent mediator of 
immunomodulation by helminths (Maizels 2004, Dittrich 2008). Therefore, active TGF- was 
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measured at the site of inflammation either in BALF in the asthma model or TGF-1 mRNA 
in skin tissues in the dermatitis model. In both approaches TGF- levels were decreased in the 
helminth infected-groups. With regard to the asthma model, the data could indicate reduced 
fibrosis or already completed wound healing in lungs of OVA/Hp-mice rather than a lack of 
mediator, as it was also observed with Av17 treatment. This notion is supported by data on 
asthmatic individuals which clearly show increased TGF- levels in the lung (Vignola 1997, 
Kenyon 2003). In contrast, in atopic dermatitis TGF- is produced by keratinocytes after 
tacrolimus treatment and thereby presumably involved in downregulation of inflammation in 
eczema regions (Lan 2004). Furthermore, TGF-ß was described to be the factor that cured 
skin lesions in the murine NC/Nga atopic dermatitis-model (Sumiyoshi 2002). Hence, these 
data lead to the conclusion that reduced TGF- levels might favour increased eczema in 
OVA/Hp-mice whereas they might indicate less fibrosis in the asthma model. 
Several studies provide evidence for a role of regulatory T cells in helminth-induced 
amelioration of allergic airway hyperreactivity (Wilson 2005, Kitagaki 2006, Leech 2007). In 
accordance with a previous study on the role of Tregs in H. polygyrus infection (Rausch 
2008) the present study points out, that the frequency of effector/memory-like Treg cells 
increased significantly in the mesenteric lymph nodes draining the site of helminth infection 
in both models of allergy. This regulatory T cell subset is characterized by the expression of 
the integrin E7 (CD103) and was shown to exhibit a particular high suppressive capacity 
(Lehmann 2002), especially in the context of H. polygyrus infection (Rausch 2008). Such 
activated Treg cells efficiently control inflammation in models of colitis, delayed type 
hypersensitivity and arthritis and migrate preferentially to inflamed tissue (Huehn 2004). 
Interestingly, in the asthma model a significant increase of such CD103+ Tregs in the 
peribronchial lymph nodes draining the lung was detected, but no increase of Treg numbers in 
the skin draining inguinal lymph nodes in the dermatitis model was observed. Of note, it has 
been described recently that the induction of organ-selective Treg homing strongly depends 
on the site of priming (Siewert 2007). Infections alter the manner in which allergen-reactive 
cells migrate and localize to sites such as bronchial mucosa, a process highly dependent on 
the suite of chemokines, leukotrienes and prostaglandins (Luster 2004). Gut parasites might 
interfere with host T cell localisation or release specific agonists of these mediators and/or 
their receptors (Maizels 2005). Hence, one might speculate whether effector/memory-like 
Tregs induced or expanded by a concomitant nematode infection within the mesenteric lymph 
nodes also migrate to other inflamed mucosal tissues (and the relevant draining lymph nodes) 
and thereby interfere with allergic disorders, as suggested by the data from the asthma model. 
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In contrast, such parasite-related Treg cells might fail to enter non-mucosal compartments, 
such as the skin, due to their priming in mucosa-associated lymphoid organs and the lack of 
homing receptors needed to enter such sites. The obtained data on lowered frequencies of 
effector/memory-like Tregs in skin-draining lymph nodes and absence of Foxp3-expression in 
the inflamed skin in mice infected with H. polygyrus strongly support this view, however 
further investigation is needed. Still, Hirahara and co-workers described, that in healthy 
individuals nearly all Foxp3+ Tregs within PBMCs express skin homing receptors like CLA 
(cutaneous lymphocyte antigen, Hirahara 2006) and Iellem could proof that usually natural 
Tregs express much more skin-homing than gut-homing receptors (Iellem, 2003) implying 
that Tregs in healthy individuals more likely migrate to the skin than to mucosal tissue. Worm 
infection might trigger large numbers of Treg cells to mucosal tissue or alter intergrin 
expression patterns (Weinstock 2006). In this account, very recently it was shown by Ozdemir 
and colleagues that transfer of CD4+ MLN of mice with intestinal immediate type 
hypersensitivity could induce airway hyperreactivity (Ozdemir 2007). They conclude that 
cells are able to migrate to other mucosal tissue. This would go in line with modified MLN 
from H. polygyrus infected animals being able to mediate suppression of mucosal airway but 
not skin inflammation.  
Nevertheless one has to keep in mind that the role of Tregs in atopic dermatitis is not clear: 
Verhagen (2006) observed a clear lack of CD4+ +CD25 Foxp3+ Treg cells in human A.D. skin 
samples, whereas Ou and colleagues (Ou 2004) claim that Treg numbers are even increased in 
human eczema but loose their immunosuppressive capacity. 
Taken together, the data obtained in this work suggest a critical role for Tregs at the site of 
infection. Tregs induced or activated in the context of the nematode infection might express a 
homing receptor pattern beneficial for the entry to the inflamed mucosal site and thereby 
impair further development of airway inflammation. These alterations might also account for 
unchanged or even exacerbated dermatitis, as Tregs might not be able to enter cutaneous 
compartments and draining lymph nodes due to impaired homing abilities. 
Infection with helminths (Schistosoma mansoni, hookworm; Araujo 2006, Leonardi-Bee 
2006) has been reported to be negatively associated with human asthma. In contrast a human 
study analysing Trichuris trichiura infection indicated rather an aggravated than a reduced 
risk of A.D. in such patients (Haileamlak 2005). In a recent study in Cuba it turned out that  
A. lumbricoides infection (life cycle with migration through host) protected against atopic 
dermatitis in children whereas infection with Enterobius vermicularis (strictly enteric life 
cycle) was associated with increased risk of atopic dermatitis (Wördemann 2008). These 
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studies strongly suggest that the species and localization of the parasite might be crucial for 
ameliorative or detrimental effects on different allergic diseases. In this context, future studies 
with skin-dwelling nematodes (as Acanthocheilonema viteae or Onchocerca volvolus) might 
reveal new mechanisms regarding allergic skin-disease and also help to unravel the positive 
effects on A.D. found with A. viteae cystatin. 
In summary, this study with the mouse nematode Heligmosomoides polygyrus provides 
explanations for the discrepancy among asthma and atopic dermatitis. A lack of Tregs at the 
site of inflammation in the atopic dermatitis model and a clear boost of Treg numbers in the 
draining lymph nodes in the asthma model are indicative. Hence, elementary differences in 
immune cell recruitment and cytokine production due to the nematode infection in different 
disease settings were observed and therefore intestinal helminth infections seem not to be 
thoroughly useful to improve allergic reactions (Figure 46). In this respect defined parasite 
components, as the detailed described cystatin, will be a better option to take advantage of the 
modulatory capabilities of helminth infections. 
 
Figure 46: Differential outcome of H. polygyrus infection in two models of allergic disease. Mucosa-associated 
airway inflammation is ameliorated by H. polygyrus infection, indicated by strongly decreased eosinophilia in 
lung, ablated allergen-specific IgE antibodies and Th2 cytokines. Parasite-specific Th2 cytokines and more 
importantly regulatory T cells are clearly increased, resulting in a modified Th2 response and downregulated 
disease. In contrast, cutaneous disease is not improved by infection with the gastrointestinal parasite. Mast cells 
in challenged skin are increased, allergen-specific Th2 cytokines are not downmodulated and no increase in Treg 
numbers in the draining ILN is found. This results in inflammation. Furthermore Treg cells induced in the gut 
seem not to be able to migrate to the skin but to migrate into lung mucosa.  
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5. Outlook 
Filarial cystatin has been shown to bear great potential to interfere with distinct allergic 
diseases and macrophage-mediated colitis (Schnoeller 2008). In the future it will be of great 
interest to apply cystatin in more clinically relevant allergy models, such as the birch pollen 
allergen Betv1 or house dust mite allergen Derp1, in order to prove cystatin`s applicability in 
the clinics. Furthermore, other disease model as DTH (delayed type hypersensitivity, EAE 
(experimental autoimmune encephalomyelitis) or SLE (systemic lupus erythematosus) should 
be tested to determine the priority field of application. 
One important aspect will be to make sure that cystatin treatment does not impair immune 
responses against other pathogens. This might be done in listeria or influenza infections 
“challenged” with cystatin applications. 
Another aspect to be tested is the exact mechanism of cystatin action in vivo. Receptor 
screening and gene expression analyses to identify the cellular receptor and the signalling 
cascade are planned. 
In addition, B cells and dendritic cells should be monitored to gain more information on 
interaction partners and cellular networks employed. This might be done by transfer 
experiments, in knock-out mice or by specific cell depletion. 
Finally, studies to exclude cross-reactions of filarial cystatin with human allergens have to be 
carried out by IgE ELISA of sera of atopic patients. 
Concerning worm infection and allergy, future studies have to concentrate on parasite biology 
and localization. Helminths associated with cutaneous tissue should be investigated in distinct 
disease models. Furthermore, experiments to analyze the migration pattern of gut-induced 
versus skin-induced Tregs will provide further insight on the underlying mechanisms. 
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6. Material and Methods 
6.1. Molecular biology and protein biochemistry methods 
6.1.1. Expression and purification of recombinant Acanthocheilonema viteae cystatin  
A pET Av17 clone was incubated overnight at 37°C in 30 ml LB medium containing 50μg/ml 
kanamycin. 10 ml of overnight culture was used to start large scale cultures (300-500 ml), in 
which expression of the protein was induced by addition of 1mM IPTG isopropylgalactoside 
for 3 h when cultures reached an optical density OD600 of 0.6. After centrifugation (4 °C, 
6,000 rpm, 15 min) pellets were resuspended in 10-20 ml lysis buffer containing lysozym and 
incubated 30 min on ice. Lysates were sonificated (3 min, 20 %) and centrifuged again (4 °C, 
12,000 rpm, 15 min) to get protein containing supernatants. The protein was purified by 
affinity chromatography using Ni-NTA resin (Diagen, Hilden, Germany) and glycerol-PBS-
buffer (10 % glycerol/PBS buffer; buffers B). Recombinant Av17 was eluted via pH gradient 
(pH6, 5, 3) subsequently neutralized by addition of neutralization buffer and dialyzed against 
PBS/0.05 % Triton X-100.  
Each lot of rAv17 had to be tested for its biological activity. Therefore, the protein was 
analyzed for its suppressive effect on polyclonal proliferation of mouse splenocytes in 
response to concanavalin A. Furthermore, cysteine proteinase inhibitor function was tested in 
activity test to papain cleavage. Cystatin was incubated with papain and the substrate BAPNA 
and inhibition of substrate cleavage by papain was measured. 
6.1.2. Purification of recombinant Cysele2, DHFR and mAv17  
Cysele2 (C. elegans cystatin 2) was induced as described before (6.1.1.) and supernatants 
were purified using FPLC and urea buffer. Elution was performed with pH shift (pH 6.4,  
pH 5.9, pH 4.5). To express recombinant mouse dihydrofolat reductase (DHFR) the procedure 
was similar to Av17 except that bacterial cultures contained 50 μg/ml kanamycin and  
100 μg/ml ampicillin. Furthermore recombinant DHFR was purified by an imidazol gradient 
(buffers A) using FPLC (fast performance liquid chromatography) and HiTrap FF columns 
(similar to Ni-NTA). 
A mutated version of Av17 (mAv17) with point mutations in the active centres for cysteine 
proteinase inhibitor activity was purified similar to Av17 and DHFR, via NiNTA-matrix and 
pH shift. 
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Endotoxin concentration Av17: 2.5 pg / μg protein = 0.05 EU per application; DHFR: 2.8 pg / 
μg protein = 0.056 EU per application; Cysele2: 2.0 pg / μg protein = 0.04 EU per 
application; mAv17: 2.5pg / μg protein = 0.05 EU per application. 
6.1.3. Endotrap system to remove endotoxin contaminations 
To remove endotoxin contaminations, Endotrap red columns were used according to the 
manufacturer´s instructions (Profos, Regensburg, Germany). 
6.1.4. Limulus amoebocyte test (endotoxin measurement) 
Final endotoxin concentrations were detected by limulus amoebocyte lysate (LAL) test 
(Cambrex, Bio Sciences, Walkersville, USA) according to manufacturer’s instructions. 
6.1.5. Quantification of protein 
Protein concentrations were measured with the bicinchoninic acid test using BCA protein 
assay kit (Pierce) according to manufacturer’s instructions (Pierce, USA).  
6.1.6. SDS-PAGE (sodium-dodecyl-sulfate polyacrylamid-gelelectrophoresis) and 
          coomassie staining 
SDS-PAGE was used to determine expression, purity and size of induced proteins. SDS-
PAGE separates proteins according to their size. Differences in polarization are mainly 
eradicated by denaturation with -mercaptoethanol and heat and binding of anionic SDS to 
the proteins in constant ratios. According to the expected size of the wanted protein separation 
gels of 12-14 % polyacrylamid were used, always with a 6 % stacking gel. Gels were run at 
120V/400mA. To visualize proteins gels were stained 30 min at 60 °C with coomassie 
staining solution. Unbound coomassie was washed away with de-staining solution. 
6.1.7. Dialysis 
Protein preparations were dialysed against PBS/0.005 % Triton over night and additional  
2 hours next day in fresh buffer if not indicated differently. 
6.1.8. RNA and cDNA preparation of lung and skin tissue and cultured cells 
For RNA preparation tissues or cells were frozen in liquid nitrogen and then ground with ice-
cold mortar and pistil. The powdered material was then treated according to manufacturer’s 
instructions of RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by digestion of DNA 
using the RNase-free DNase-Set (Qiagen) according to the manufacturer’s instructions.  
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RNA was reverse-transcribed using the TaqMan Reverse Transcription Reagent (Applied 
Biosystems, Warrington, UK) and oligo dTs. The PCR conditions were 10 min 25 °C, 30 min 
48 °C, 5 min 95 °C.  
6.1.9. Real time PCR (TaqMan-System) 
The basic principle of real time PCR is the fluorescence resonance transfer (FRET). FRET is 
the phenomenon when two fluorochromes with overlapping adsorption and emission energy 
act as reporter and quencher. This means that if the two fluorochromes are in close contact the 
emission energy of the reporter will be transferred to the quencher and therefore the emission 
energy of the quencher and not of the reporter is set free. Real time PCR uses this 
phenomenon by the application of a gene-specific probe (oligonucleotide with reporter and 
quencher fluorochrome in close contact) that is destroyed by the 5´-3´-exonuclease activity of 
the polymerase when it amplifes the sequence. The more amplificates are produced the more 
reporter is set free and the fluorenscence signal increases. The amount of original mRNA can 
be recalculated and set into relation to a housekeeping gene as described below. Real time 
PCR was used to analyse the expression levels of several cytokines at the site of inflammation 
/ in the tissue (mRNA levels). The 7300 Real-Time PCR System (Applied Biosystems, New 
Jersey, USA) and TaqMan reagents were used to do so. PCR amplifications were done in 
triplicates containing 3 μl of cDNA, 2 μl of 20x TaqMan labelled primer mix and 10 μl of 2x 
TaqMan PCR buffer. The 20x TaqMan primer mix consisted of two unlabeled PCR primers 
(900 nM each final concentration) and 1FAM™ dye-labelled TaqMan®MGB probe (250 nM 
final concentration). All primers were obtained from Applied Biosystems (IL-4 Assay ID: 
Mm00445259_m1, IL-10 Assay ID: Mm00439616_m1, TGF-ß Assay ID: Mm 00441729_g1, 
Foxp3 Assay ID: Mm00475156_m1, IFN- Assay ID: Mm00801778_m1, GAPDH Assay ID: 
Mm99999915_g1). PCR conditions were set to 10 min denaturation at 95°C followed by 40 
amplification cycles of 15 s at 95°C and 60 s at 60°C. The relative amounts of cytokine 
mRNA were normalized to the endogenous reference, the house keeping gene GAPDH. 
Calculation of expression profiles was done using the 2-Ct –method. In this method a 
threshold is set according to the cycle number where the individual reactions start to get 
exponential. The program calculates Ct-values (Ct = cycle threshold) for each sample, which 
reflect the cycle number at which each sample reaches the given threshold. Ct values of the 
endogenous control were subtracted from the correlating samples to normalize samples. Mean 
values of sample triplets were then compared to controls (either negative or positive control) 
and calculated as described earlier (Livak 2001). 
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6.2. Cell culture techniques 
6.2.1. RBL assay 
RBL assay was performed to analyse antigen-specific IgE in sera. RBL (rat basophile 
leukemia) cells were maintained in Eagle’s minimum essential medium with 10 % RPMI, 5 % 
fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 g/ml) and L-glutamine  
(2 mM). Cells were plated in 96-well flat bottom plates (105 cells/well). Passive sensitization 
of the cells was performed by 1 h incubation with 50 μl mouse serum diluted 1:50 in culture 
medium. Cells were washed with Tyrode’s buffer and for cross-linking 5μg/ml OVA or 
5μg/ml Av17 diluted in Tyrode’s buffer for 1 h was added. Spontaneous and total release was 
measured by incubation of cells with Tyrode’s buffer without antigen and addition of 1 % 
Triton X-100 respectively. -hexosaminidase release was measured in 30 μl supernatant and 
the enzymatic activity was detected by addition of 50 μl of the substrate p-nitrophenyl N-
acetyl ß-d-glucosaminide (1.3 mg/ml in 0.1 M citric buffer, pH 4.5). The reaction was stopped 
with 100 μl 0.2 M glycine solution ph 10.7 and absorbance was measured at 405 nm. Total 
release was set to 100 % and results are expressed as percentages. 
6.2.2. Preparation of mesenteric lymph node cells (MLNC), splenocytes, inguinal (ILNC) 
          and peribrochial lymph node cells (PBLNC) 
MLN, PBLN, ILN and spleen were isolated aseptically from euthanized mice. Organs were 
dissociated by passing them through a steel mesh in PBS pH 7.4 containing 0.2% BSA to 
obtain single cell suspensions. Erythrocytes were removed by resuspension of washed cells in 
erythrocyte lysis buffer for 5 min on ice. After washing, cells were adjusted to desired 
concentrations in cRPMI for culture or PBS/BSA for surface stainings and flow cytometry 
analysis.  
In the asthma model spleen mononuclear cells were isolated by density gradient 
centrifugation (Lympholyte-M, Cedarlane Laboratories, Hornby, Ontario, Canada).  
Cells were cultured with a density of 5 x 105 cells/well in RPMI 1640 (10 % FCS, Pen/strep, 
L-Glu and fungi) for 96 hours in the presence of 50 μg/ml OVA, 10 μg/ml Av17, 10 μg/ml 
DHFR or 2,5 μg/ml concanavalin A (ConA). Cell culture supernatants were stored at -20 °C 
until performance of cytokine ELISA.  
6.2.3. Peritoneal lavage and preparation of peritoneal exudate cells (PEC) 
To obtain PEC the peritoneal cavity of sacrificed mice was washed 4 to 5 times with 2 ml ice-
cold RPMI. Cells were centrifuged and lysis of erythrocytes was performed. Afterwards cells 
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were seed in 96 well plates at a density of 2.5 – 3.0 x 105 cells/well in complete RPMI. For 
some experiments medium was changed after 2h and cells were left to adhere another  
12 hours before stimulation with antigen. Cell culture supernatants were stored at -20 °C until 
performance of cytokine ELISA. 
6.3. Animal models 
6.3.1. Animals used for experiments 
Female BALB/c mice (Ol1a-Hsd) were purchased from Harlan Winkelmann (Borchen, 
Germany) or the BfR, Berlin respectively. For asthma experiments mice were kept in ivc-
cages, for other experiments animals were housed with filter caps. All mice were housed and 
handled following national guidelines and as approved by the animal ethics committee.  
6.3.2. Murine asthma model and measurement of airway hyperreactivity (AHR) 
Female BALB/c mice (Harlan-Winkelmann, Bachem, Germany) were sensitized twice (day 0 
and day 14) intraperitoneally with 20 μg OVA (grade VI, Sigma-Aldrich, Steinheim, 
Germany) emulsified in 2 mg of aluminium hydroxide (ImjectAlum, Pierce, Rockford, 
USA). On days 28 and 29, mice were challenged intranasally with 50 μg OVA (25μl per 
nostril). Airway responsiveness was measured in unrestrained and conscious mice on day 31. 
After provocation by inhalation with rising dosages of the bronchostringent metacholin 
(MCh), AHR was subsequently determined in a full body plethysmograph. The pressure 
difference between the plethysmograph chamber containing the animal and a reference 
chamber was assessed. This difference during the respiratory cycle can be indicated as 
enhanced pause (PenH) using mathematical formulae and can be taken as an index for 
respiratory constriction amongst the experimental animals (Hamelmann 1997c).  
A baseline of breathing was recorded as reaction to inhalation of PBS. These baseline values 
were subtracted from values obtained in response to stimulation with 6.25 mg/ml, 12.5 mg/ml, 
25 mg/ml and 50 mg/ml metacholine. Measurements were performed for each 
bronchoconstrictor concentration for 3 minutes and values obtained were evaluated as 
follows: Data was filtered to ensure that only measurements with a success rate (Sr) of more 
than 50 % were included. Furthermore only Penh values that correlated with a pressure (EIP) 
lower than 10 and Te values bigger than Ti values were used for calculation. The mean values 
of the Penh (pause enhanced) for every MCh concentration was calculated and index Penh 
values of individual animals (Penh value of MCh minus baseline) were analysed as mean 
values of groups.  
81 
Material and Methods 
One day after assessment of airway hyperreactivity mice were sacrificed and the following 
analyses were carried out: 
- lavage of the lung to assess BALF and cell numbers and types pointing to 
inflammation 
- removal of spleen to perform cell culture and proliferation assays 
- removal of lymph nodes (peribronchial (PBLN), mesenteric (MLN)) to perform FACS 
analysis and / or cell cultures 
- cryoconservation of parts of the lung to perform Real-Time-PCR 
- preparation of lungs for histological analysis (formalin or cryo) 
- assessment of blood to monitor antibody production 
Within the model 20 μg recombinant A. viteae cystatin in a total volume of 200μl diluted in 
low-endotoxin PBS or the same amount of control protein DHFR was injected 
intraperitoneally four times in weekly intervals during the sensitization (d 1, 7, 14, 21; 
preventive model), or three times after sensitization with ovalbumin prior to airway allergen 
challenges (d 21, 23, 25; pre-challenge model). Naïve control animals were treated with PBS 
in aluminium hydroxide intraperitoneally and challenged with PBS intranasally.  
6.3.2.1. Bronchoalveolar lavage (BAL)  
Animals were sacrificed by cervical dislocation and lungs were lavaged twice using a tracheal 
drain tube with 0.8 ml of cold PBS/EDTA (proteinase inhibitor tablets, (completeTM Mini)). 
The volume of the lavages was measured by weighing and after centrifugation (10 min,  
2.000 rpm, 4 °C) supernatants of the first lavages were stored at -20 °C for cytokine analyses. 
The cell pellets of both lavages were resuspended in a total of 1ml PBS, cell numbers were 
counted and 100μl of the cell suspensions was used to prepare cytospin slides. Cytospin slides 
were stained with DiffQuick (Dade Behring AG) and bronchoalveolar lavage (BAL) cells 
were differentiated by morphological criteria (count of 200 cells under light microscopy), as 
previously described (Blümchen 2006). 
6.3.2.2. Histological analysis of lung 
Lungs were either filled with Tissue Tek OCT compound (Jung) solution after removal and 
frozen in liquid nitrogen or put in 3.5 % formalin to be embedded in paraffin later on. Slices 
of 5μm were cut and afterwards stained with he (hematoxilin/eotaxin) to monitor cells types 
and infiltration in lung tissue or stained with PAS/H to visualize mucus production in 
bronchioles (Edwan 2004). Slides were analysed regarding bronchioles and their surrounding 
by light microscopy with a 40- and 400- fold magnification. 
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6.3.3. Murine dermatitis model (atopic eczema) 
Mice were sensitized i.p. on days 1, 14 and 21 with 10 g ovalbumin (OVA, Sigma-Aldrich) 
adsorbed to 10 g aluminium hydroxide (ImjectAlum) in 100 μl PBS or with phosphate 
buffered saline (PBS) and alum as control. Epicutaneous (e.c.) allergen application was 
performed as described previously (Spergel 1998). Each mouse had a total of three one-week 
exposures to the same skin site. Naïve animals were treated e.c. with PBS/Alum. At day 70 
mice were sacrificed and skin biopsies, spleen, lymph nodes and blood samples were 
collected for further analysis.  
To evaluate the severity of OVA-induced eczematous skin lesions, standardized clinical skin 
score (CSS) based on clinical features of human A.D. (Leung 1990) was used, which 
considers typical skin features of A.D., like erythema, edema/papules, oozing/crusts, dryness 
and extension (Matsuda 1997). For total CCS the marked lesions that were visible on the 
patched skin area were graded as 0 (none), 1 (mild), 2 (moderate) and 3 (severe) by two 
independent persons. The total score was taken as index of dermatitis severity (Dahten 2008). 
Within the model 20 μg recombinant A. viteae cystatin in a total volume of 200 μl diluted in 
low-endotoxin PBS or the same amount of control protein DHFR was injected 
intraperitoneally six times on day 1, 7, 14, 21, 42 and 63. Naïve control animals were injected 
with PBS on cystatin application days. 
6.3.3.1. Histological analysis of skin 
Skin samples were embedded in Tissue Tek OCT compound. Frozen tissue blocks were cut 
into 5 m sections and fixed in acetone. For histological analysis sections were stained with 
hematoxylin for 1 min. Thickness of epidermis and dermis was determined by Axiovisions 
measuring-tools on the Axioplan light microscope (Zeiss) at 100 x magnification. Ten 
measurements per mouse were obtained and expressed in micrometers. 
6.3.3.2. Immunohistochemistry of skin sections 
Sections of 4 m were prepared as described above, blocked with 10 % normal goat serum 
(Dako) and incubated with rat anti-mouse CD4 (clone RM4-5) and anti-mouse CD8 (clone 
53- 6.7) followed by incubation with biotinylated goat anti-rat IgG. CD11c positive cells were 
detected by usage of purified hamster anti-mouse antibody (HL3) and biotinylated anti-
hamster IgG cocktail (all BD Pharmingen, Heidelberg, Germany). To rule out unspecific 
binding of antibodies, negative controls without primary and/or secondary antibodies were 
performed, respectively. Signals were detected by Chem-Mate® alkaline phosphatase/red 
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detection Kit (Dako) and by hematoxylin counter staining. To determine infiltrating mast 
cells, 5m skin sections were stained for 1h with o-toluidine blue. Positive stained cells were 
counted in 10 high power fields (HPFs) at x 200 magnification and expressed as cells per 
HPF. 
6.3.4. Depletion of Treg cells and blocking of IL-10 receptor in vivo 
Treg cells were depleted by intraperitoneal application of 100 μg anti-CD25 antibodies (clone 
PC61, gift A. Scheffold, DRFZ, Berlin) 5 days prior to challenge/analyses. Treg depletion 
was confirmed by flow cytometry surveying expression of CD4, CD25 and CD103 
coexpression. An isotype-matched antibody (Rat IgG) was used as control. 
Anti-IL-10 receptor antibodies (clone 1B1) were applied three times intraperitoneally 500 μg 
each time along with filarial cystatin. An isotype-matched antibody (Rat IgG) was used as 
control. 
6.3.5. Depletion of macrophages / Preparation of multilamellar vesicles (MLV) 
            containing clodronate 
Clodronate liposomes were prepared as described by Van Rooijen elsewhere (Van Rooijen 
1994). In brief, an emulsion of 86 mg/ml phosphatidylcholin and 8 mg/ml cholesterol in 10 
ml chloroform was vacuum evaporated and multilamellar vesicles emerged by gentle shaking 
with 10 ml clodronate suspension (0.6 M, 0.25 mg/ml) or PBS under nitrogen conditions. The 
vesicles were kept under nitrogen gas (2 h) and sonicated in a waterbath sonicator for 3 min. 
The suspension was kept under N2 over night for swelling of the liposomes. The liposome 
solution was centrifuged 15 min at 10,000 g and remaining clodronate removed. The 
clodronate was sterile filtered and reused up to 5 times to avoid spoiling. MLVs were washed 
with sterile PBS twice (30 min, 25,000 g) and resuspended in the same buffer.  
Macrophages were depleted by intranasal and intraperitoneal application of clodronate 
liposomes two days prior to challenges (100 μl per application). Macrophage depletion was 
confirmed by flow cytometry (see above) or histological cell differentiation (see BALF), 
respectively.  
84 
Material and Methods 
6.4. Immunological methods 
6.4.1. Enzyme-linked immunosorbent assay 
6.4.1.1. Serum levels of IgE (total and OVA-IgE), OVA-IgG1, OVA-IgG2a 
Total IgE levels were measured by sandwich ELISA using anti-IgE antibody as catcher,  
3% BSA in PBS to block unspecific binding, dilutions of sera (1:10, 1:100, 1:1000, 1:10000 
in blocking buffer) containing induced antibodies and anti-IgE antibody coupled to Biotin as 
detection antibody. HRP (horse radish peroxidise) labelled Streptavidin was applied in a 
1:10000 dilution to detect Biotin-labelled antibodies and binding was visualized by 
application of the HRP-substrate TMB. After stopping the reaction with 1M H SO2 4 plates 
where measured at 450/630 nm in a plate reader. IgE-standard solution was analysed in 
accordance to samples to calculate IgE amounts. 
OVA-specific antibodies where measured in an analogical manner though after application of 
diluted samples 3 μg/ml biotinylated ovalbumin was used to detect exclusively OVA-specific 
IgE antibodies. To calculate amounts, purchasable IgG1-standards or IgE-and IgG2a standard 
sera were used, respectively. OVA-specific IgE and IgG2a are therefore calculated as lab 
units (LU) and not in μg (Beier 2004).  
immunoglobulin Capture ab standard Detection ab 
Total IgE IgE 10μg/ml PC284 IgE 250ng/ml IgE-Bio 2,5μg/ml 
The binding site 557079 Pharmingen 553414 
Pharmingen 
OVA-IgE IgE 2μg/ml OVA-Standardserum #67 
1:64 
OVA-Bio 3μg/ml 
553413 Pharmingen 
OVA-IgG1 IgG1 2μg/ml OVA-spec. IgG1 340ng/ml 
A6075 Sigma 
OVA-Bio 3μg/ml 
553445 Pharmingen 
OVA-IgG2a IgG2a 2μg/ml OVA-Standardserum #67 
1:64 
OVA-Bio 3μg/ml 
553387 Pharmingen 
6.4.1.2. Biotinylation of ovalbumin 
1ml of a 1mg/ml solution of OVA grade VI (pH 8.3 with 100 mM NaHCO3) was incubated 
1h with 13.4 M sulfo-NHS-LC-Biotin (20 μl) at RT, shaking, in the dark. Afterwards the 
solution was purified of unbound biotin by size exclusion chromatography (application of 
PD10-sephadex column). 
6.4.1.3. Subclass - specific ELISA 
200 ng/well of the referring protein was coated in carbonate buffer overnight and plates were 
blocked with 3 % BSA/TBS. Sera were applied in 1:50 dilution (in 1 % BSA/TBS) and 
antibody subclasses were detected by use of subclass-specific AP(alkaline phosphatase)-
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labeled detection antibodies and AP-substrate BCIP (5-Brom-4-chlor-3-indoxylphosphate) 
and NBT (Nitroblue-Tetrazoliumchlorid). Reaction was abrogated with EDTA and measured 
at 405/630 nm in ELISA reader. 
6.4.2. Cytokine detection 
IL-4, IL-5, IL-10, IFN- and TNF- measurements were performed using OptEIA ELISA kits 
according to manufacturer’s instructions, but using 50 μl of samples and standards/well.  
TGF- was analysed by R&D TGF- ELISA kit also according to manufacturer’s 
instructions. To measure TGF-ß in cell cultures cells were cultivated in RPMI/1 % 
FCS/1mg/ml BSA in order to reduce background levels. In several experiments cytokine bead 
arrays to analyse G-CSF, IFN-, IL-1, IL-2, IL-4, IL-5, IL-10, IL-12p40, IL-13, KC, 
RANTES, Eotaxin and TNF- simultaneously were performed (mouse Bio-13-Plex assay) 
according to manufacturer’s instructions. 
6.4.3. Flow cytometric analysis  
Surface staining of lymphocytes using mAb was performed in PBS/0.2 % BSA on ice and in 
the dark for 15 min. Cell suspensions (1x106 total cells) were washed in PBS/BSA and stained 
with CD4, CD25 and CD103 to detected Treg cells. Macrophages in peritoneal excudate 
cells (PEC) were stained for CD3 and CD19 to exclude T and B cells and detected by 
F4/80- staining. Unspecific binding of the mAbs was blocked by the addition of FcRII/III 
(20 μg/ml). Intracellular detection of Foxp3 was performed according to the manufacturer’s 
instructions. Non-specific intracellular binding was blocked with whole rat IgG. Cytometric 
analysis was performed using FACS Calibur or LSRII and FlowJo software. 
6.4.4. Proliferation assay 
Standard proliferation assays were performed by culturing 2.5 x 105 splenocytes in 96 well 
plates. Cells were stimulated with protein or mitogen for 24h. Subsequently 1 μCi 3H-
Thymidin per well was added for another 20 h. The uptake of labelled thymidin was measured 
by scintigraphy and reflects proliferation rate in cpm (counts per minute). 
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6.5. Parasitological methods 
6.5.1. Life cycle of Heligmosomoides polygyrus 
Heligmosomoides polygyrus was maintained by serial passage in BALB/c mice. Mice were 
infected with approx. 200 L3 using a feeding tube. Infective larvae were obtained from fecal 
cultures. Feces were collected from infected animals, washed in distilled water and plated in 
Petri dishes on humid blotting paper for 7 days. On d7, L3 were washed from the plate and 
kept in distilled water at 4 °C after extensive washing. L3 were used for infection up to 8 
weeks after fecal culture. Mice in experiments were infected with a defined dose of L3. The 
adult worm burden was determined by collecting adult worms from the small intestine on the 
day of dissection. 
6.5.2. Fecal egg count 
To monitor the status of H.polygyrus infection feces were analysed for egg output regularly. 
Feces of individual mice were collected, weighed and suspended in 1 ml aqua dest. by a 
mortar. Subsequently 5 ml saturated NaCl-solution was added and 650 μl of the solution put 
onto MacMaster chambers to count eggs via light microscopy. EPG (eggs per g feces) was 
calculated by the following formulae: 
Number of eggs in sample x volume x 6.67 x (1/ feces weight in g). 
6.5.3. Preparation of H. polygyrus adult worm antigen 
Soluble worm antigen was prepared from adult worms kept in culture in RPMI medium 
containing 100 U/ml penicillin and 100 μg/ml streptomycin for 24 h. Worm material was 
homogenized and sonicated (1 min, 60W) on ice in PBS (pH 7.4). The homogenate was 
centrifuged (20 min, 20.000g, 4 °C) and the supernatant was passed through a 0.4 μm filter 
for sterilization. Antigen extracts were stored at –80 °C until application.  
6.6. Statistical analysis 
Each experiment was performed with 5–6 animals/group, and the experiments shown are 
representative of two to three independent experiments unless stated otherwise. Statistical 
analysis was performed with the two-tailed Mann-Whitney U test. Data are presented as 
means +/- SE. Values of p < 0.05 were considered to be statistically significant. 
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6.7. Material 
6.7.1. Laboratory equipment 
Flow cytometer: LSRII BD Biosystems, San Jose, CA 
ELISA-reader Dynatech, Denkendorf, Germany 
 BioTek, Vermont, USA 
Scintillation-spectroscope Trilux 1450 Wallac, Turku, Finland 
Ultrasound-disintegrator Heinemann, Schw. Gmünd, 
Germany 
Real-time PCR system 7300 Applied Biosystems, Foster City,  
  CA 
whole-body plethysmograph (AHR) emka technologies, Paris, France 
Cytocentrifuge (cytospin) ThermoShandon, Frankfurt, 
  Germany 
6.7.2. Buffers and media 
FACS staining buffer PBS / 0.2 % BSA 
FACS fixation buffer PBS / 0.2 % BSA /  
2 % paraformaldehyde 
Erythrocyte lysis buffer pH 7.5 0.01 M KHCO3 
 0.155 M NH4Cl 
 0.1 mM EDTA 
Cell culture medium (cRPMI) RPMI-1640 
 5-10 % FCS 
 20 mM L-glutamine 
 100 U/ml penicillin 
  100 μg/ml streptomycin 
  all from Biochrom, Berlin, 
  Germany 
Protein purification buffers 
PBS/ pH 7,4  137 mM NaCl 
 2.7 mM KCl  
 8 mM Na HPO
2 4  
 1.5 mM KH PO
2 4  
DHFR 
Lysis buffer A/ pH 7,4  300 mM NaCl  
 50 mM NaH PO
2 4  
 20 mM Imidazol  
Wash buffer A/ pH 8  300 mM NaCl  
 50 mM NaH PO
2 4  
 30 mM Imidazol 
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Elution buffer A/ pH 8  300 mM NaCl  
 50 mM NaH PO
2 4  
 250 mM Imidazol  
Av17 
Lysis buffer B/ pH 8 PBS 
Wash buffer B/ pH6  PBS  
 10 % (v/v) Glycerin  
Elution buffer B/ pH 4  PBS  
 10 % (v/v) Glycerin  
Neutralisation buffer/ pH9  1 M Tris 
mAv17 
Lysis buffer/ pH 8 PBS/0.1 % (v/v) Triton 
Wash buffer/ pH 5.8 PBS/10 % (v/v) Glycerin 
Elution buffer/ pH 3 PBS/10 % (v/v) Glycerin 
Neutralisation buffer/ pH10 PBS 
Cysele2 
Lysis buffer/ pH8  8 M Urea 
 100 mM NaH PO2 4 
 10 mM Tris  
Wash buffers/ pH6.3 and pH5.9 see lysis buffer 
Elution buffer/ pH4.5 see lysis buffer 
Dialysis 1/ pH7.4  1 M Urea 
 0.1 M NaH PO2 4 
 10 mM Tris 
Dialysis 2/ pH7.4 PBS 
Dialysis 3/ pH7.4 PBS/0.05 % (v/v) Triton 
LB-medium 10 g Trypton  
 10 g NaCl  
 5 g yeast extract  
 ad. 1 l H O dest.  
2
Activity test reaction buffer 0.2 M K HPO2 4 
 0.2 M KH PO2 4 
 0.004 M DTT 
 0.004 M EDTA 
 0.01 % (v/v) Brij 
BAL-solution PBS (Dulbeccos w/o) 
 Complete mini protease
 inhibitor 
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6.7.3. Chemicals, biologicals and recombinant cytokines 
3H Thymidin ICN, Costa Mesa, USA 
BSA, fraction V AppliChem, Darmstadt, Germany 
BAPNA (92μM) Bachem, Weil a. Rhein, Germany 
Proteinase inhibitor cocktail Roche, Mannheim, Germany 
Paraformaldehyde Sigma, München, Germany 
Papain (100μM) Sigma, München, Germany 
6.7.4. Commercial Kits 
Foxp3 detection kit  eBiosciences, San Diego, CA 
(clone FJK-16s, PE-coupled) 
OptEIA ELISA kits  BD Biosciences, Heidelberg, 
Germany 
TGF- ELISA-set R&D Systems, Minneapolis, MN 
BCA kit Pierce, USA 
 TaqMan primer and probes Applied Biosystems, Darmstadt, 
Germany 
TaqMan cDNA synthesis kit Applied Biosystems, Germany 
TaqMan PCR master mix Applied Biosystems, Germany 
RNeasy Mini kit Qiagen, Hilden, Germany 
QIAshredder spin columns Qiagen, Hilden, Germany 
LAL QCL-1000 Cambrex, USA 
Cytokine bead array 13-Plex R&D systems, Minneapolis, USA 
Profos endotrap system red Profos, Regensburg, Germany 
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6.7.5. Antibodies and secondary reagents 
Specificity fluorochrome clone Purchased from 
PE 145.2C11 DRFZ* CD3 
FITC/PerCP RM4-5 BD Biosciences CD4 
FITC ID3 DRFZ* CD19 
APC/PerCP-Cy5.5 PC61 BD Biosciences CD25 
PE M290 BD Biosciences CD103 
- (biotin) M290 DRFZ* CD103  
F4/80 Cy5 F4/80 DRFZ* 
IL10R - 1B1 Falk, Rötschke** 
FcR  - 2.4G2 DRFZ* 
Rat IgG - polyclonal Dianova 
Secondary reagents    
SA-PE-Cy7 PECy7  BD Biosciences 
SA-PE PE  BD Biosciences 
* mAb was a kind gift of the German Arthritis Research Centre. 
** mAb was a kind gift of Dr. K. Falk and Dr. O. Rötschke, MDC Buch 
6.7.6. Software 
FlowJo (Tristar) 
BD FACSDiva (BD Biosciences) 
Prism (GraphPad)
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7. Abbreviations 
Ab antibody 
A.D. atopic dermatitis 
Ag antigen 
APC allophycocyanin 
APC antigen presenting cell 
AHR airway hyperreactivity 
Av17 Acanthocheilonema viteae 17kDa immunomodulator (cystatin) 
BAL bronchoalveolar lavage 
BALF bronchoalveolar lavage fluid 
Bio biotin 
BSA bovine serum albumin 
CD cluster of differentiation 
DC dendritic cell 
DHFR dihydrofolat reductase 
e.c. epicutanous 
ELISA enzyme-linked immunosorbent assay 
EU endotoxin unit 
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
Foxp3 forkhead box transcription factor p3 
FSC forward scatter 
G G force 
GM-CSF granulocyte-macrophage colony stimulating factor 
HDM house dust mite 
Hp Heligmosomoides polygyrus 
h hour 
IFN interferon 
Ig immune globuline 
IL interleukin 
IL-10 R interleukin-10 receptor 
ILN inguinal lymph node 
ILNC inguinal lymph node cell 
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i.n. intranasal 
i.p. intraperitoneal 
KO knock out 
LU lab unit 
μg microgram 
μl microliter 
mg milligram 
ml milliliter 
M molar 
mAb monoclonal antibody 
MHC major histocompatibility complex 
min minute 
MLN mesenteric lymph node 
MLNC mesenteric lymph node cell 
MLV multilamellar vesicle 
ng nanogram 
NK natural killer cell 
NO nitric oxide 
OVA ovalbumin 
PBLN peribronchial lymph node 
PBLNC peribronchial lymph node cell 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PEC peritoneal excudate cells 
Penh pause enhanced 
pg picogram 
RT room temperature 
SA streptavidin 
Treg regulatory T cell 
Th1 T helper cell 1 
Th2 T helper cell 2 
TGF transforming growth factor 
TNF tumor necrosis factor
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